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Abstract 
Positional proteomics is emerging as an attractive technique to characterize 
protein termini, which play important biological roles in cells. Even with the 
advances in past decades, there still are areas for improvement. This thesis focuses 
on improving data quality and assignment confidence in positional proteomics.  
A novel workflow was designed for the large-scale identification of protein 
N-terminal sequences. 4-sulfophenyl isothiocyanate (SPITC) is used for N-termini 
sulfonation; Upon higher energy collisional dissociation (HCD), SPITC peptides in 
electrospray ionization ESI generate predominately y-type ion series; such 
simplification of spectra enables the identification of N-termini with high fidelity. 
The presence of b1 + SPITC product ions upon HCD furthers the confidence for N-
terminal identifications.  Secondly, sulfonated N-terminal peptides possess one 
negative charge site at low pH, which was exploited to enrich the SPITC modified 
N-terminal peptides by electrostatic repulsion hydrophilic interaction (ERLIC) 
chromatography. Such enrichment process allows both N-termini enriched and N-
termini deficient fractions to be collected and analyzed by LC-MS/MS. This 
method was applied to an E. coli cell lysate, identifying approximately 350 N-
terminal peptides (85% represented neo-N-termini from protein degradation and 
15% from leading methionine excision). These N-terminal peptides represented 
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274 distinct E.coli proteins, 224 of which were also identified in the analysis of 
flow-through fractions from internal peptides.   
Another approach we took to boost the identification confidence is by 
exploiting iTRAQ (isobaric tag for relative and absolute quantitation) in the 
positional proteomics workflow. This approach allows for multiplexed comparison 
between different samples, and thus is well-suited for degradadomics analyses 
where degraded samples are compared to control samples.  Both control and 
protease treated sample are labeled by different tags which allows direct 
comparison of protein N-termini with neo-N-termini. In addition, samples are 
analyzed duplicate by labeling with two tags, aiming for quick validation of 
peptides by internal replicates. In this study, Asp-N digested E.coli cell lysate is 
taken as a model system. A total of 500 N-terminal peptides, corresponding to 370 
proteins, were identified with high confidence in one experiment, with 87% of 
those proteolytic products matching the expected protease digestion specificity, 
validating the assignment accuracy of this approach. 
Keywords: Positional proteomics; Sulfonation; SPITC; ITRAQ modification. 
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Chapter 1. Introduction 
1.1 Introduction of Proteomics 
Proteomics is the large-scale study of proteins particularly their structures 
and functions.1,2 Proteomics is the next step in the study of biological systems after 
genomics and transcriptomics, since proteins are vital parts of living organisms as 
the main components of the physiological metabolic pathways of cells. Mass 
spectrometry (MS) has increasingly become a key technology for protein sequence 
analysis in the past decade, especially for complex mixtures, due to significant 
advances in instrumentation, sample preparation techniques and data interpretation 
algorithms. 
Large scale, “bottom-up” (also called “shotgun”) characterization of cellular 
proteomes is the most widely adapted method in proteomics study.3,4,5,6,7,8,9,10 A 
typical workflow for high-throughput bottom-up characterization is composed of 
protein extraction from cells, enzymatic digestion, LC-MS/MS analysis and 
database searching which correlate MS/MS spectra with sequence and ultimately 
the parent proteins.  
Proteome systems typically encompass thousands of individual components 
present in concentrations ranging over several orders of magnitude;11 therefore, to 
reduce the complexity, multidimensional liquid chromatography (MDLC) is 
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generally used for fractionation prior to MS analysis.12 , 13  The combination of 
online/offline strong cation exchange (SCX) with reversed-phase (RP) 
chromatography is the most widely used MDLC due to the good orthogonality of 
the methods.14,15,16 Peptides are separated by charge in SCX and by hydrophobicity 
in RP. The use of high concentrations of salt in SCX may cause problems in 
downstream analysis; therefore, online desalting of the collected fractions from 
SCX with the trap column is the common practice,17 even with the drawback of a 
high tendency for autosampler blockage and quick deterioration of the trap 
column. Extensive separation of components aids in the protein coverage; it is now 
possible to identify more than 10,000 proteins from human cells.18,19 
1.2 Isobaric Labeling in Proteomics 
A major aspect of proteome research is quantitative proteomics aiming at 
measuring relative changes in proteins expressed in cells or tissues of different 
states, e.g. healthy versus disease state.20,21,22,23,24 Measurement of relative changes 
is simplified when two or more analytes can be labeled distinctly, combined, and 
analyzed as a mixture. Labeling schemes based on isotopic labeling, in which all 
labeled versions of a single peptide co-elute from LC, are especially powerful, as 
the relative abundance for this peptide corresponds directly to the relative signal 
intensity due to identical ionization efficiencies. Accordingly, a significant effort 
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has been made to develop stable isotopic labeling methods to facilitate downstream 
MS analysis for direct comparison.25,26,27,28 
Isotopic labeling with stable isotopes is a well-known method for "tagging" 
specific proteins. Such metabolic labeling is applicable to cell culture, e.g., through 
growth in isotope-labeled media (e.g., 15N media29,30). Another approach is stable 
isotope labeling by essential amino acids in cell culture (SILAC)31,32 which  relies 
upon addition of intact isotopically-labeled amino acids. The most commonly used 
stable isotope-encoded amino acids are 13C6-lysine or 13C6-arginine.33,34,35,36 The 
biggest advantage of SILAC compared to other isotope labeling techniques is that 
the SILAC technique offers minimum technical variations in sample processing 
due to the fact that the isotope is introduced into the cell culture, the earliest 
possible sample mixing stage. 
Most in vitro labeling techniques are based on the formation of a covalent 
bond between the labeling reagent and the specific functional groups in 
polypeptides. Isotope-coded affinity tag (ICAT) is among the first of such 
applications reported in 1999.37 ICAT consists of three elements: an iodoacetamide 
group to modify cysteine residues, an isotopically coded linker, and a biotin tag for 
the affinity isolation of labeled proteins/peptides (refer to figure 1.1). The process 
starts with ICAT labeling, followed by trypsin digestion, then, the ICAT labeled 
peptides are enriched by affinity chromatography via a biotin tag, resulting in 
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reduction of sample complexity. The concept is innovative and widely accepted.38 
However, the method provides limited coverage over the proteome, as the cysteine 
content in proteins is fairly low giving poor coverage of the digested peptides, and 
many proteins have no cysteine. 
Among all the isotopic labeling techniques, the iTRAQ (isobaric tags for 
relative and absolute quantification) method shows significant advantages.39,40,41,42 
The iTRAQ reagent reacts with proteolyzed peptides to form an NHS ester 
derivative with primary amino groups. Differentially labeled peptides appear as 
single peaks in MS scans due to the isobaric mass design of the iTRAQ reagent 
(refer to figure 1.1); such multiplication of peptide abundance results in 
improvement of sensitivity. When subjected to MS/MS, the isotope encoded 
reporter ions provide relative quantitative information on peptides and ultimately 
on proteins (refer to figure 1.2). In a complex mixture, iTRAQ samples subjected 
to independent data acquisition in LC-MS/MS have a tendency to allow 
identification of only high abundance proteins in a traditional proteomics 
workflow. Both 4-plex and 8-plex versions of iTRAQ are commercially available.  
In this thesis, effort has been made to incorporate iTRAQ with positional 
proteomics to monitor protease substrates in E. coli cell lysates. 
 
 Figure 1.1 Scheme for chemical labeling of ICAT and iTRAQ
 
Figure 1.2 Illustration of MS and MS/MS of iTRAQ labeled peptide
 
1.3 Positional Proteomics
The concept of positional proteomics is that a protein can be identified by a 
single, position-defined peptide, with the two most obvious positional locations 
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within every protein being the N- and C-termini. 43  Sample complexity is 
dramatically reduced in N-terminal or C-terminal enriched samples of proteolytic 
digests. There are two driving forces in this field to motivate the advance of this 
technology. One is the proteome annotation,44 where the termini play important 
roles in protein function, mutation and post translational modification.45 ,46  The 
other is the development of degradomics,47,48 which focuses on the elucidation of 
protease substrate and cleavage sites. The newly generated termini after protease 
treatment are called neo-N-termini or neo-C-termini, in order to differentiate them 
from mature (innate) protein termini. 
To identify terminal peptides, the normal proteomics workflow is no longer 
suitable due to the fact that the terminal peptides are buried in the sea of internal 
tryptic peptides. The sample complexity makes it difficult to select and detect the 
terminal peptides during MS/MS acquisition. Therefore, terminal peptide 
enrichment prior to MS analysis is essential in such workflow development. 
Enrichment greatly simplifies the proteome by using single terminal peptides for 
protein identification, which increases dynamic range and proteome coverage for 
low abundant proteins.  
It is essential to differentiate the termini peptides from the internal peptide in 
positional proteomics, since the same functional groups that define the protein 
termini in the sample, i.e. α-amine and carboxyl groups are presented by internal 
 proteolyzed peptides.  In addition, primary amine and carboxylic groups are 
present in the side chains of lysine and acidic amino acid residues, respectively. 
The following paragraphs summarize strategi
positional proteomics.  
Positional proteomics workflow can be roughly divided into the following 
modules shown in figure 1.3: (1) labeling of termini, (2) proteolysis, (3) 
enrichment, and (4) LC-MS/MS analysis.
Figure 1.3 Typical positional proteomics workflow
 
The enrichment process can be categorized as either
approach or a negative selection approach. The former modif
tag that enables targeted enrichment of
mixture. The latter takes advantage of the newly generated functional groups 
(primary amine for N-termini and carboxylic acid for C
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1.3.1 Positional Proteomics approach for N-terminal analysis  
1.3.1.1 Enrichment of protein N-termini by positive selection using 
biotinylation 
A method using biotinylation to positive select N-terminal peptides was 
reported by Kuhn et al in 2003.49 This protein tag technology was later on adapted 
and further developed by the Salvesen lab to identify protease substrates.50 In this 
method, the side chains of lysine are first blocked by guanidination, and then free 
alpha-amines (protein N-termini) are reacted with a disulfide-linked biotin 
derivative (sulfosuccinimidyl 2-(biotinamido)-ethyl-1, 3-dithiopropionate (sulfo-
NHS-SS-biotin)). After trypsin digestion, the peptide mixture is incubated with 
immobilized streptavidin beads, which retains the N-terminal peptide. The last step 
of sample preparation is to elute the N-terminal peptide by reducing the disulfide 
bond. This workflow was applied to study in vivo constitutive proteolysis in E. 
coli, yeast, mouse and human samples and determine the specificity of methionine 
aminopeptidases, signal peptidases and mitochondrial peptidases.  
Another biotinylation protocol was reported by Wells et al. based on subtiligase 
in 200851. An engineered variant of subtilisin called subtiligase was used, which 
shows absolute selectivity for ligation of alpha-amines, forming a biotinylated 
peptide ester containing a tobacco etch virus (TEV) protease cleavage site. Proteins 
9 
 
are then denatured, reduced and alkylated before trypsin digestion. Then, the 
biotinylated N-terminal peptides are captured by immobilized streptavidin, 
resulting in the separation from internal and C-terminal peptides. The N-terminal 
peptides are eventually released by TEV digestion, with tagging of Ser-Tyr-
dipeptides at the N-termini as a signature for identification by LC-MS/MS. The 
subtiligase method was validated by analysis of the proteome of living and 
apoptotic Jurkat cells. It was reported that 333 unique cleavage sites in 282 
proteins were identified after aspartic acid residues and were therefore linked to 
caspase activity in etoposide treated apoptotic Jurkat cells. A separate study using 
this technique combined with SILAC in cell culture to identify caspase-1 substrates 
in vitro and in cell-based inflammation models was also reported.52 
A third biotinylation method incorporated Edman degradation in the 
workflow 53 . After protein is denatured, reduced and alkylated, phenyl 
isothiocyanate (PITC) is used to block all primary amines in the proteome. Then, 
trifluroacetic acid is used to break the peptide bond between the first and second 
amino acid of PITC modified proteins, while PITC modified ε-amines (i.e. lysine 
side chains) remain intact in this treatment. The next steps are similar to the 
aforementioned method. The newly generated free α-amine is biotinylated with 
sulfo-NHS-SS-biotin, followed by trypsin digestion. Streptavidin is used to trap 
biotinylated peptides, which is further released by disulfide bond reduction. The 
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enriched N-terminal peptides in this case are one amino acid shorter than the true 
N-termini. This approach was validated by a mixture of known proteins and 
applied to characterize the constitutive N-terminal processing events in Jurkat 
cells. Both known and new caspase substrates were identified in the cisplatin-
induced apoptosis of Jurkat cells. 
A fourth biotinylation-related method in degradomics is called PICS 
(proteomic identification of protease cleavage) developed by the Overall lab54. 
This approach differs from the other approaches in that it is peptide centric and not 
protein/substrate centric. First, proteins are digested by trypsin or endoproteinase 
Glu-C, and then all primary amines are blocked by methylation. The peptide 
mixture is treated as a library and incubated with a protease of interest. Neo-N-
terminal peptides are biotinylated and affinity-selected, followed by LC-MS/MS 
analysis. This approach was applied to profile serine (thrombin, neutrophil 
elastase, cathepsin G), aspartic (HIV-1 protease) and cysteine proteases (cathepsin 
K, caspase-3, caspase-7).55 
The advantage of positive selection using biotinylation is the high efficiency of 
enrichment due to the high specificity between biotin-streptavidin. A drawback of 
this type of technique may arise from amino acid bias during the biotinylation 
reaction. For example, the secondary α-amino group of proline is less reactive 
compared to the primary α-amino group of other amino acids.56 In addition, in 
11 
 
positive selection, mature proteins with acetylation, dimethylation or cyclization at 
N-termini will not be detected. 
1.3.1.2 Enrichment of protein N-termini by negative selection using 
biotinylation 
McDonald et al43 reported a protocol based on biotinylation for negative 
selection in 2005. Here, all the primary amines in a proteome sample are acetylated 
first, followed by trypsin digestion. The internal peptides and C-terminal peptides 
containing an α-amino group at a newly generated N-termini are biotinylated and 
removed by passing through immobilized streptavidin beads. The simplification 
effect was shown in chicken skeletal muscle and E. coli cell lysate.  
1.3.1.3 Enrichment of protein N-termini by negative selection using amine 
reactive reagent 
There are a few reports using amine reactive reagents to scavenge the newly 
generated internal peptides after digestion, thus enriching N-terminal peptides. The 
basic workflow is as follows: (1) The primary amines in proteins are acetylated or 
dimethylated, followed by trypsin digestion. (2) The internal peptides and C-
terminal peptides are scavenged by amine reactive reagent and the flow through, 
which contains enriched N-terminal peptides, is collected.  
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McDonald et al57 used NHS activated Sepharose beads to scavenge internal 
peptides in 2006 and reported the identification of about 300 E. coli protein N-
termini.  
Mikami and Takao used an isocyanate resin to capture internal peptides.58 The 
performance of isocyanate resin was demonstrated by applying it to several peptide 
mixtures, including proteolytic digests.  
Kleifeld et al47 employed a self-synthesized dendritic polyglycerol aldehyde 
polymer to capture tryptic and C-terminal peptides, which can be conveniently 
removed by centrifugation.  It is claimed that the binding of tryptic peptides of 
such polymer is up to 2.5 mg peptide/ mg polymer, a more than ten-fold 
improvement in capacity over amine reactive resins. This approach incorporated 
with isotopic labeling under various formats is a valuable venue for N-terminal 
positional proteomics research and it is further explained in the following section 
of N-TAILS.  
1.3.1.4 Protein N-terminal identification by N-terminal amine based 
isotope labeling of substrates (N-TAILS) 
A detailed and streamlined protocol of N-TAILS was described by the Overall 
lab in 2011, 59  based on previous development and applications by the same 
lab.45,60,61 The highlight of TAILS is that it uses negative selection to enrich for all 
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N-terminal peptides and uses primary amine labeling-based quantification as the 
discriminating factor. Labeling is versatile; the authors elaborate dimethylation-
TAILS, SILAC-TAILS and iTRAQ-TAILS in the current protocol. This method is 
suited to many applications, including biochemical and cell culture analysis in 
vitro as well as analysis of tissue samples from animal and human sources in vivo.  
The TAILS workflow is composed of the following steps (refer to figure 1.4): 
protein collection and proteolysis by the test protease; isotopic labeling and 
primary amine blocking followed by tryptic digestion; negative selection by a high 
efficiency polymer (dendritic polyglycerol aldehyde polymers); identification of 
N-terminal peptides by LC-MS/MS; identification of protease substrates by the 
sequence of the cleavage sites, or loss of cleaved natural N-terminal peptides. 
To improve coverage, it is recommended to employ two or more digesting 
proteases other than trypsin, e.g. Glu-C or chymotrypsin.  
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Figure 1.4 Scheme for N-TAIL workflow 59 
1.3.1.5  Enrichment of protein N-termini using phosphor tagging (PTAG) 
and TiO2-based depletion 
Mommen et al62 described a protocol to enrich protein N-terminal peptides 
using phospho tagging (PTAG) and titanium dioxide (TiO2) affinity 
chromatography. Primary amino groups in proteins are initially dimethylated with 
formaldehyde, followed by digestion using trypsin, chymotrypsin and 
endoproteinase Glu-C. The newly formed internal peptides are modified with the 
PTAG reagent glyceraldhyde-3-phosphate in nearly perfect yields (>99%). The 
resulting phosphopeptides are removed by binding onto TiO2 affinity column. This 
method allowed identification of 753 N-terminal peptides, corresponding to 428 
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proteins, in N. meningitides and 928 N-terminal peptides, corresponding to 572 
proteins, in S. cerevisiae.  
1.3.1.6 Enrichment of protein N-termini by combined fractional diagonal 
chromatography (COFRADIC)  
In 2003, the N-terminal combined fractional diagonal chromatography 
(COFRADIC) technology introduced by the Gevaert lab63 was the first positional 
proteomics technology by which N-terminal peptides were enriched by depleting 
other peptides (refer to figure 1.5). This method progressed in the following 
years64,65,66,67,68and the latest protocol was reported in 2011.69 The protocol can be 
briefly described as the following: Before trypsin digestion, proteins undergo 
denaturation, reduction and alkylation. Then, all primary amines are blocked by 
trideutero-acetylation (to distinguish in vitro acetylation from in vivo acetylation) 
so that trypsin digestion will produce only Arg-ending peptides. The peptide 
mixture is incubated with glutamine cyclotransferases and pyroglutamyl amino 
peptidases, respectively, to convert N-terminal glutamines into pyroglutamates and 
remove these pyroglutamates from the peptide backbone. The above mixture is 
then loaded onto an SCX cartridge at low pH, where N-terminal blocked peptides 
are poorly retained and are collected in the flow through fraction since they carry 
one less positive charge compared to internal peptides at low pH. This peptide 
mixture is then separated in RP-HPLC and primary fractions are collected. Each of 
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the above collected fractions are treated with 2,4,6-trinitrobenzenesulfonic acid 
(TNBS), which reacts with the primary amine of any remaining internal peptides to 
introduce a very hydrophobic trinitrophenyl group with these peptides. Each 
treated fraction is put through the second RP-HPLC separation using identical 
chromatographic conditions as in the first separation, where the N-terminal 
peptides elute within the same time interval as during the primary run, however, 
the TNBS modified internal and C-terminal peptides carrying a large hydrophobic 
group elute much later in RP-HPLC, thus resulting in separation from the neo-N-
terminal and protein N-terminal peptides.  
 
Figure 1.5 Scheme for COFRADIC for N-terminal peptides 63 
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The COFRADIC technology has been applied in various biological systems 
and has been proved to be a reliable approach for protease-related studies. Stable 
isotopes for labeling purpose are introduced in the protocol in biological 
applications. Oxygen-18 was used to label peptides during trypsin digestion in a 
human Jurkat cell culture; a total of 93 in vivo protease-processed sites in 71 
proteins associated with Fas-induced apoptosis were identified. Oxygen-18 
labeling together with COFRADIC was also used to map the proteolytic process in 
anthracycline-induced acute myelogenous leukemia cell death.66 
SILAC can also be incorporated into the COFRADIC workflow (refer to 
figure 1.5), Arginine is chosen for SILAC labeling, since tryptic digestion 
produces arginine-ending peptides. The control cells use regular arginine in cell 
culture while the sample cells use 13C6 arginine in cell culture. Purified proteins in 
the heavy labeled cells are treated with protease, and then combined with the 
purified proteins in control cells. The following steps are the same as normal 
COFRADIC. More than 800 cleavage sites in 332 human and 282 mouse 
substrates for granzyme b were identified using SILAC combined with 
COFRADIC.70  
1.3.2 Positional Proteomics approach for C-terminal analysis  
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Generally speaking, C-terminal analysis is not as widely available as the N-
terminal analysis due to the formidable technical difficulties of selective activation 
of carboxylic acids. Current methods of isolating C-terminal peptides are 
predominantly affinity-based procedures. The application of mass spectrometry to 
C-terminal analysis in the literature related to our topics is as follows: 
1.3.2.1 Use anhydrotrypsin-lysine affinity to isolate the C-terminal 
peptides 
An elegant approach to isolate C-terminal peptides was reported in 2000.71 
Basically, a sample is digested with endoprotease Lys-C, and then anhydrotrypsin 
coupled onto agarose beads is applied to the digest sample. Anhydrotrypsin is a 
catalytically inert variant of trypsin capable of binding peptides with C-terminal 
lysine or arginine. Thus, the N-terminal and internal peptides are bound to 
anhydrotrypsin beads; after centrifuging to get rid of beads, the supernatant only 
contains the original C-terminal peptides for further analysis. However, this 
method is not suitable for proteins ending with lysine or arginine (~ 84% of 
proteins do not end with lysine or arginine). This approach lacks robustness; the 
amount of anhydrotrypsin beads was adjusted for each of the proteins investigated. 
The reason is that a small amount of anhydrotrysin beads is not sufficient to 
capture the internal peptides, while a large excess of beads will induce non-specific 
19 
 
binding of C-terminal peptides to the beads. For a complex system with a large 
dynamic range, the integrity of the results cannot be ensured.  
1.3.2.2 Use of DITC resin to isolate C-terminal peptides 
In an approach described by Kuyama et al., a sample is initially digested with 
endoprotease Lys-C, then TMPP modification is selectively applied to cap the N-
terminal amino group. The reagent for TMPP modification is 
succinimidyloxycarbonylmethyl tris (2,4,6-trimethoxyphenyl) phosphonium 
bromide (TMPP-Ac-Osu). p-Phenylenediisothiocyanate (DITC) resin is used to 
scavenge the lysine-containing peptides from a Lys-C digest. Isolated C-terminal 
peptides are then de novo sequenced using MALDI-MS/MS.72 This method has 
been further optimized73 to use diisothiocyanate coupled glass beads. This method 
is not suitable for proteins ending with lysine or arginine.  
1.3.2.3 Use of polymer-based enrichment for C-terminal peptides 
Overall et al74 reported a polymer-based enrichment approach to profile protein 
C-terminal peptides. Briefly, the workflow is as follows (refer to figure 1.6): 
protein thiol groups are reduced and alkylated, carboxyl groups of C termini, 
aspartate and glutamate side chains are then protected by carbo-diimide-mediated 
(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, EDC) and N-
hydroxy succinimide-assisted condensation with 1 M excess of ethanolamine. The 
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derivatized proteins are then digested by trypsin. To prevent cross-reactivity, 
peptide concatamerization or cyclization, free amines are protected with methyl 
groups. The internal tryptic and N-terminal tryptic peptides are removed by 
coupling with polyallylamine (MW ~56000, sigma) mediated with EDC. 
Ultrafiltration is used to remove the polymer, retaining the enriched C-terminal 
peptides in solution. LC-MS/MS follows to analyze the sample.  
This approach is the first that allows proteome-wide C-terminal analysis.  In the 
same report, C-terminal amine-based isotope labeling of substrates (C-TAILS) was 
also described, in which heavy isotope formaldehyde is used during both reductive 
methylation steps. C-TAILS was tested using a Glu-C digested E. coli cell lysate 
model system. The result showed that more than 90% of the peptides identified had 
C-termini corresponding to the Glu-C cleavage site.  
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Figure 1.6 scheme of proteome wide C-termini analysis by Overall lab 74 
1.3.3 Positional Proteomics approach for both N and C-terminal analysis  
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o The C-terminal ends with lysine or arginine.  
o Trypsin digestion has a missed-cleavage, resulting in peptides with 
multiple basic residues. 
In such circumstances, the terminal peptides will possess at least two free 
amines, thus their charge properties change and they are no longer able to be 
separated from the internal peptides. The author also pointed out that the selective 
recovery of acetylated N-terminal and C-terminal peptides depends on the trypsin 
digestion integrity.  
1.3.3.2 Combined fractional Diagonal Chromatography (COFRADIC) for 
simultaneous N and C terminal proteomics 
In 2010, the Gevaert lab48 published a COFRADIC workflow for both N and 
C- terminal peptide identification in a single sample preparation. This COFRADIC 
workflow follows the procedures described in N-terminal COFRADIC, except that 
after the primary fraction collection, peptides are reacted with an N-hydroxy-
succinimide ester of butyric acid, butyrylating the C-terminal peptides. Such 
modification allows C-termini to elute 4-12 min after N-termini in secondary RP-
HPLC. The pooled N-terminal and C-terminal peptides are ready for LC-MS/MS 
analysis. The authors used this COFRADIC based approach to study processing by 
the human endoprotease granzyme B in K-562 cell lysates. SILAC of 13C6 arginine 
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cell lysate is used as substrate pool for granzyme B, with 12C6 arginine cell lysate as 
control. Thus, upon trypsin digestion, neo-N-terminal peptides can be 
differentiated from the N-termini background of the cell lysate. C-termini are 
differentiated by using N-hydroxysuccinimide (NHS) esters of 12C4 or 13C4 butyric 
acid. In this study, a total of 1621 annotated N-termini and 760 annotated C-
termini were identified, with 334 neo-C termini resulting from granzyme B 
processing and 16 neo-C termini resulting from carboxypeptidase A4 processing.  
1.3.4 Thesis overview 
With all the efforts and advances in positional proteomics, the inherent main 
drawback of such techniques still needs to addressed, which is how to validate the 
identified substrates due to the “one hit wonder” in such technique.  The strength 
of positional proteomics arise from the dramatically reduced complexity of 
proteome samples, however, the strength turns into weakness if the question is 
asked how you can validate the results. In this thesis, we propose an approach 
which separates the enriched N-termini fraction for positional proteomics from the 
peptide mixtures, while preserving the rest of the peptide mixture. Therefore, MS 
analysis of the remaining peptide mixtures can serve as validation for the results of 
positional proteomics. Such direct experimental validation is meaningful and 
convincing considering both analyses use the same starting material. The above 
goal is achieved by utilizing 4-sulfophenyl isothiocyanate (SPITC) to modify the 
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N-termini and separate the SPITC modified peptides from others using 
electrostatic repulsion hydrophilic interaction chromatography (ERLIC). 
Moreover, the confidence of N-termini identification is further strengthened by 
exploiting the unique fragmentation behavior of SPITC peptides, thus we conclude 
that our approach offers high fidelity assignment of N-terminal peptides. This work 
is presented in chapter 3.  
Another attempt to simultaneously validate the results of positional 
proteomics is by use of iTRAQ-4plex. In this study, both control and protease 
treated samples are labeled by different tags which allows direct comparison of 
protein N-termini with neo-N-termini. In addition, samples are analyzed in 
duplicate by labeling with two tags (i.e. tag 116 and tag 117), aiming for quick 
validation of peptides by internal replicates. A new workflow is designed which 
incorporates iTRAQ into positional proteomics to study the specificity of protease. 
This work is presented in chapter 4.  
Experimental optimization is shown in chapter 2. A summary of study is 
presented in chapter 5.  
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Chapter 2 Experiments toward a streamlined workflow for 
positional proteomics 
2.1 Overview of method 
The workflow starts by converting lysine to homoarginine by guanidination, 
followed by sulfonation of N-termini by 4-sulfophenyl isothiocyanate (SPITC). 
After trypsin digestion, electrostatic repulsion hydrophilic interaction (ERLIC) 
chromatography is used to enrich SPITC modified peptides. Both the flow-through 
fraction (containing internal and C-terminal peptides) and eluted fraction 
(containing SPTIC modified N-terminal peptides) are analyzed by LC-MS/MS. A 
specialized N-terminal database with sequentially trimmed N-termini is used to 
identify N-terminal peptides from degraded proteins.  
2.2 Consideration for development 
The two critical aspects for any positional proteomics workflow are terminal 
labeling and enrichment. To identify minor species in a complex mixture, some 
sort of enrichment for the minor species is required.  There are various approaches 
and efforts described for this topic in the literature as summarized in chapter 1. N-
terminal enrichment approaches can be categorized into three pathways, namely 
chemically or enzymatically positive selection of N-termini,1,2 negative selection 
(scavenging the internal and C-terminal peptides) 3  and the application of ion 
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exchange chromatography4 based on the charge differences among N-terminal , C-
terminal and internal peptides. Both negative and positive selection approaches 
were tested in our study, the results of which are described later in this chapter.   
The second critical aspect is the manner of labeling of the protein termini. 
Here we choose to use SPITC for labeling N-termini. SPITC derivatization is 
predominantly applied to proteolytic peptides in the literature,5 so our development 
effort was focused on modifying the protocol to make it work on complex mixtures 
of intact proteins with high efficiency. Guanidination was performed prior to 
SPITC, which converted lysine to homoarginine by blocking the side chain of 
lysine. Therefore, SPITC derivatization only occurred at the N-terminal site and 
was assigned as such during data interpretation. 
Besides the two aspects mentioned above, the overall workflow was 
streamlined, particularly with respect to protein/peptide purification steps.  
2.3 Optimization 
Experiments designed to optimize each step are presented in this section in 
the same order as the steps in the workflow. These are: guanidination reaction, 
SPITC reaction, protein purification, trypsin digestion, enrichment, LC-MS/MS 
and database searching.  
2.3.1 Guanidination reaction 
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The purpose of guanidination is to selectively cap the side chain of lysine, 
thus leaving only the N-terminal amine for the next step in the SPITC reaction. The 
reaction is selective, except when glycine is the N-terminal amino acid; in such 
cases the primary amine group of glycine can also be modified.6 The guanidination 
reaction is performed as reported by Reilly et al.7 
A standard peptide with the sequence 
TNEIVEEQYTPQSLATLESVFQELGK  (m/z 2952.4; m/z for guanidination 
product is 2994.4) was used to monitor this reaction. The conversion rate was 
computed as the area of m/z 2994.4 divided by the sum of the areas of m/z 2952.4 
and m/z 2994.4 obtained from LC-MS. The concentration for isourea was 300 mM, 
the starting material of peptide was 0.12 mM and only 1 µL was used for each 
reaction. 10 µl NH4OH with 15 µL isourea is the recommended condition by the 
kit vendor (Sigma Aldrich).  The conversion was around 90%. Doubling the use of 
isourea or hydroxide did not increase the conversion rate. Due to the downstream 
SPITC derivatization of primary amines, the introduction of a large quantity of 
ammonium ions is undesirable, so NH4OH was replaced with 10 µL of 0.1 M 
NaOH.  While this change in the base caused the conversion rate to drop 
significantly to around 25%, further study determined that titrating the reaction 
with NaOH to pH 10 produced a comparable conversion rate to that for the 
reaction using NH4OH (Table 2.1).   
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Table 2.1 Guanidination optimization 
base  isourea (µl) 
conversion 
rate 
NH4OH-10 µl 15 85.7% 
NH4OH-10 µl 15 92.0% 
NH4OH-10 µl 30 85.0% 
NH4OH-20 µl 30 89.6% 
NaOH (0.1 M)-10 µl 30 24.6% 
NaOH (0.1M)-10 µl 30 25.2% 
NaOH pH 10 15 89.7% 
NaOH pH 10 15 87.4% 
 
Notably, the reaction completeness is 90% in our measurement using LC-
MS/MS, which is lower than in a reported study by MALDI-MS.7  Such 
discrepancy may arise from the mass spectrometer employed.  In MALDI-MS, the 
high gas-phase basicity of guanidinated lysine facilitates proton capture and 
charging in the positive ion mode. Thus, ionization of guanidinated lysine peptides 
occurs more efficiently than for the non-guanidinated lysine-containing peptides 
that are characterized by a lower gas-phase basicity. When the two are present as a 
mixture, the former can capture protons more efficiently, and thereby, the signal of 
the latter may be suppressed.  In contrast, in LC-ESI-MS, the non-guanidinated 
standard peptide and the guanidinated reaction product were separated by LC 
before MS detection, facilitating detection of the minor species.  
2.3.2 SPITC labeling 
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The SPITC reaction protocol followed the description by the Cotter lab.8 
Specifically, a solution of SPITC was freshly prepared at 50 mg/mL in 20 mM 
sodium bicarbonate buffer (pH 9). The guanidinated protein mixture was adjusted 
to pH 9 by addition of NaOH (1 N). A 100-fold molar excess of SPITC was added 
to the mixture.  The mixture was then incubated at 65 °C for 1 hour.  
Using the peptide AAAAK (1 mg/mL in water) as a model compound, the 
SPITC modification (50 mg/mL in 20 mM sodium bicarbonate buffer (pH 9)) was 
100% complete as determined by LC-MS after incubating at 65 °C for one hour 
with all tested conditions listed in Table 2.2. This reaction is robust as long as 
ammonium-based buffer is avoided.  
Table 2.2 Evaluation of SPITC reaction conditions 
AAAAK (µl) SPITC (µl) conversion 
10 20 100% 
10 40 100% 
10 60 100% 
10 80 100% 
  
2.3.3 Isolation/Purification 
It is easy to test reaction conditions with peptides, where the contaminant 
reagents can be diverted to waste by an on-line valve switch in HPLC or be 
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removed by off-line C18 cartridge clean-up. When dealing with protein 
purification, it is common to use trichloro-acetic acid (TCA) or ice cold acetone to 
precipitate protein into pellet and to follow with a wash. However, once the 
proteins aggregate into pellets, it is extremely difficult to bring them back into 
solution. While solubilization can be promoted using urea or guanidine 
hydrochloride, these denaturants are problematic for the downstream trypsin 
digestion and require additional cleanup efforts. Therefore, we endeavored to find 
an approach that avoided protein precipitation entirely. Alternatively, the excess 
reagents can be removed by dialysis.  However, this method usually takes days to 
complete and is therefore undesirable.  
A desalting Zeba column (7k MWCO) from Thermo Scientific was used to 
isolate/purify proteins in our workflow, allowing the proteins to remain in solution 
all along the process.  The success of this approach may arise from the increase of 
the basicity of lysine due to the guanidination reaction; this increased basicity 
promotes the solubility of denatured proteins in mild buffer. Following the 
protocol depicted in the product booklet, Zeba spin desalting columns are buffer 
exchanged 4 times with 300 µL of 50 mM ammonium acetate (or other buffer 
suitable for the following enzymatically digestion) by centrifuging for 1 min at 
1500 g, then no more than 130 µL of protein is loaded on top of the resin bed, and 
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samples are collected after centrifuging for 2 min at 1500 g. The whole process 
takes less than 10 min. We adapted this process in the final workflow. 
2.3.4 Trypsin digestion 
Trypsin (Promega, sequence grade) is added at an enzyme/substrate ratio of 
1:50 to the buffer exchanged sample. The sample is then incubated at 37 degrees 
overnight. No further modification was made to the digestion condition.  
2.3.5 Enrichment  
The enrichment step occurs after trypsin digestion.  Two enrichment 
methods were tested. In the end, the iTRAQ application (Chapter 4) used NHS 
activated agarose beads for enrichment, while the SPITC approach (Chapter 3) 
used the ERLIC method. 
2.3.5.1 N-termini enrichment by NHS activated agarose spin column 
We first tested negative selection by scavenging the internal and C-terminal 
peptides through commercially available NHS activated agarose spin columns 
(Thermo Scientific), due to the simplicity of this approach. Following the protocol 
in the brochure, the whole process took one hour. After desalting using C18 
cartridge, the sample was analyzed using LC-MS/MS. The effectiveness was 
demonstrated in Figure 2.1 using BSA (50 µg starting material) as a testing 
protein.  Before enrichment, the modified N-termini were at a low abundance level 
 (insert of the top figure in figure 2.1) compared to other peptides when averaging 
the total ion chromatogram (TIC) over the range of HPLC elution. After 
enrichment, the abundance of N
as one of the major components in 
six most abundant m/z values 
430.26, 561.32, 547.32 and 464.25
these six peptides are also marked in Figure 2.1B. S
observed for all six peptides. 
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-terminal peptides was raised and became 
the TIC over the full HPLC elution range. 
before enrichment including m/z at 480.61, 516.79, 
 are marked in Figure 2.1A, the counterparts of 
ignificant intensity drop
  
 
 
present 
The 
s are 
 
 Figure 2.1 Comparison between before (A) and after (B) enrichment by NHS activated 
agarose resin spin column for BSA sample.  N
DTHK(guandinyl)SEIAHR   m/z= 484.20
This approach also worked well for the iTRAQ
4). However, unsatisfactory results were obtained using the NHS
resin spin column to process an 
peptides. For 100 µg of E. coli
annotated N-terminal peptides. A second round of enrichment generated a total of 
13 annotated N-terminal peptides, while a third round of enrichment produced only 
9 annotated N-terminal peptides. Non
NHS-activated resin may be 
the resin enrichment. Due to the inefficiency of this approach, we switched to 
charge-based enrichment for SPITC modification.
2.3.5.2 SPITC peptide enrichment by ERLIC
41 
-terminal peptides (SPITC
3+). 
-based application (Chapter 
-activated agarose 
E. coli cell lysate sample with SPITC modified 
 starting material, we were able to obtain 62 
-specific interactions of peptides with the 
the reason for the loss of N-terminal peptides during 
 
 
 
-
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We refer to the protocol by Alpert 9  for ERLIC-based enrichment. A 
PolyWAX LP, 5-µm, 300 Å, 2.1 mm x 50 cm (Poly LC Inc., Columbia, MD) 
column was used, with mobile phase A as 20 mM ammonium formate, pH 2.2 with 
70% acetonitrile; and mobile phase B as 900 mM ammonium formate, pH 2.2 with 
10% acetonitrile. To facilitate downstream MS analysis, the column was used in a 
solid phase extraction fashion and only two fractions were collected. Therefore, 
100% A was applied at the beginning for 3 minutes for the first fraction. Then, the 
mobile phase was switched to 100% mobile phase B with a one minute gradient 
and held for 10 minutes for the second fraction. The salt is volatile and is removed 
by vacuum centrifuge.  
2.3.6 Mass spectrometer selection  
High mass accuracy of parent ions and fragment ions is extremely important 
for accurate peptide sequence identification. Both Orbitrap XL (Thermo) and 
QExactive (Thermo) were used in this study. With the Orbitrap XL instrument, a 
typical workflow involves a survey scan at high resolution mode (R=30,000, FT 
mode), followed by 10 MS/MS scans at low resolution mode (trap mode). In the 
follow-up database search, mass accuracy for the parent ions was set to be 10 ppm 
and for the fragment ions at 0.8 Da.  Such low mass accuracy of fragment ions may 
very well contribute to the false identification of peptide and proteins in our 
opinion. It is possible to acquire data in high resolution mode for both survey scan 
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and MS/MS scan using Orbitrap XL, however, the cycle time is accordingly 
prolonged and the duty cycle is reduced drastically, which means much less input 
into the database, leading to less peptide and protein identification. This feature of 
the Orbitrap XL instrument impairs its application in complex system (e.g. 
proteomics) in our proposed workflow.  
Instead, QExactive is much better fit to the proposed workflow. With its 
high speed (5X faster than Orbitrap XL), both survey scans and MS/MS scans can 
be performed in high resolution mode. In the final set-up, data is acquired using 
QExactive, with one survey scan followed by 12 MS/MS scans at FT mode for 
both types of experiments. HCD mode of activation is employed for activation of 
ions. An example is shown in figure 3.5 (Chapter 3) that demonstrates that HCD 
offers much more signature ions in MS/MS spectra for peptide sequencing.  
2.3.7 Database searching 
The analysis of mass spectrometric raw data was carried out using Proteome 
Discovery 1.3 software (Thermo Fisher Scientific, Bremen, Germany) applying 
standard settings unless otherwise noted. The E. coli K12 strain database (Uniprot) 
prepared in the fashion similar to that described by Dormeyer et al10 was used for 
searching. Specifically, all protein sequences in the database were cut at arginine, 
and for each resulting peptide, multiple sequence database entries were generated 
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that represented sequential truncations of N-terminal amino acids.  Only sequences 
with 6 amino acids or longer were retained in the database. The workflow utilizing 
both SEQUEST and Mascot search was used as shown in Figure 2.2, with the 
convergence handled by Percolator. Decoy database searches were performed with 
False Discovery Rate (FDR) tolerances set to 5% and 1% for modest and high 
confidence filtering settings, respectively. Other settings are depicted in Chapter 3.   
 
Figure 2.2 Workflow for database searching 
2.4 Summary 
This chapter described method development for several key steps in the 
workflow. The application of these methods is shown in chapter 3 and chapter 4.  
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Chapter 3 High Fidelity Approach for Proteomic Scale 
Enrichment and Identification of N-termini 
3.1 ABSTRACT 
A novel workflow was designed for the large-scale identification of protein 
N-terminal sequences. The workflow started with converting lysine to 
homoarginine by guanidination, followed by reaction with sulfonation of N-termini 
by 4-sulfophenyl isothiocyanate (SPITC). Upon trypsin digestion, the N-terminal 
peptides possessed one negatively charged sulfonate site at low pH, while all 
amino acids of internal and C-terminal peptides were neutral or positively charged. 
This difference was exploited to enrich the SPITC modified N-terminal peptides by 
electrostatic repulsion hydrophilic interaction (ERLIC) chromatography in which 
the internal and C-terminal peptides eluted at the void volume, and the SPITC 
peptides were retained in the column due to the hydrophilicity and electrostatic 
attraction of the sulfonyl group to the stationary phase. Both the flow-through 
fraction (containing internal and C-terminal peptides) and eluted fraction 
(containing SPTIC modified N-terminal peptides) were analyzed by LC-MS/MS. 
A specialized N-terminal database with sequentially trimmed N-termini was used 
to identify N-terminal peptides from degraded proteins. Upon HCD, SPITC 
peptides in ESI generated predominately y-type ion series, similar to what has been 
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previously noted for MALDI MS/MS spectra of N-sulfonated species; such 
simplification of spectra enables the identification of N-termini with high 
confidence. The appearance of b1 + SPITC product ions upon HCD further boosts 
the confidence for N-terminal identifications. This method was applied to an E. 
coli cell lysate, thus allowing the identification of approximately 350 high 
confidence N-terminal peptides (85% represented neo-N-termini from protein 
degradation and 15% from leading methionine excision). These N-terminal 
peptides represented 274 distinct E. coli proteins, 224 of which were also identified 
in the analysis of flow-through fractions from internal peptides. The approach 
presented here resulted in an approximately 10-fold enrichment of N-terminal 
peptides, and greatly improved confidence for each MS/MS assignment over other 
positional proteomics approaches. 
3.2 INTRODUCTION 
Protein isoforms at N-termini and C-termini are diverse for several reasons. 
They may be generated during the course of protein biosynthesis due to alternative 
initiation of transcription within genes, by transcription processes that are 
independent of annotated gene boundaries,1-2 from post translational modification 
by mRNA splicing3 or by enzymatic protein processing.4-5  The structural changes 
occurring at protein termini often correlates with function alteration. Many human 
diseases are associated with proteolytic truncation or terminal modification;4-7 
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therefore, it is essential to characterize protein N-termini and C-termini for 
functional annotation of proteomes of interest.  
Mass spectrometry (MS) driven techniques show advantages in such 
applications due to their sensitivity, speed and selectivity in identification of 
proteins (even in complex systems such as a whole cell lysate or serum samples). 
Several strategies have been reported to selectively isolate protein N-terminal 
peptides. The technique called combined fractional diagonal chromatography 
(COFRADIC), developed by the Gevaert group, has been applied to map protease 
processed sites in human Jurkat cell cultures8, anthracycline-induced acute 
myelogenous leukemia cells9, and human A549 nonsmall-cell lung carcinoma 
cells10. In this method, the free amine of N-termini and lysine side-chains were 
tagged by acetylation with either a natural or isotopically labeled reagent, followed 
by trypsin digestion. N-termini (including the original N-termini of proteins and 
neo-N-termini generated upon proteolytic cleavage) and C-termini were enriched 
by strong cation exchange chromatography at low pH. Secondary enrichment was 
also performed using TNBS derivatization. The hydrophobicity of TNBS causes C-
termini peptides to elute at later retention times on reversed-phase columns, 
whereas N-terminal peptides elute earlier.   
In an alternative method, McDonald et al. reported a protocol for positional 
proteomics where free amine groups in proteins were first blocked by acetylation, 
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followed by N-termini enrichment by NHS-activated sepharose resin and MS 
analysis.11 Recently, the terminal amine isotopic labeling of substrates (TAILS) 
method was reported by Kleifeld et al. for identifying acetylated, cyclized N-
termini and matrix metalloproteinase (MMP)-2 cleavage sites in mouse fibroblast 
secretomes12. Here, reductive dimethylation reactions were performed on N-
termini and lysine side-chains; internal and C-terminal peptides were covalently 
bonded with dendritic polyglycerol aldehyde polymers, which were later removed 
by centrifugation. Another approach utilizing unbiased selective isolation of N-
terminal peptides using phospho-tagging (PTAG) and TiO2-based depletion was 
shown to be effective for N-terminal identification. In this approach, dimethylation 
was first performed to label N-terminal and lysine side chain amino groups at the 
protein level. Proteins were then enzymatically digested, and the newly formed 
internal peptides were modified with PTAG reagent and further depleted from the 
solution by binding onto TiO2. The high conversion rate of PTAG and high 
selectivity of TiO2 toward phospho-peptides makes this approach very attractive.  
Frequently, the value of positional proteomics is questioned due to the 
reliance on single peptides, or so-called ‘one hit wonders’13 to identify whole 
proteins, as this approach is expected to be susceptible to many false positives. 
Previous efforts to reject the false identifications involved tailoring the search 
space in the database14-15 or building post-processing tools16-17. The work herein 
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aims to reduce the number of false identifications by improving MS/MS spectral 
quality. We utilize 4-sulfophenyl isothiocyanate (SPITC), which serves to 
simultaneously aid the generation of more diagnostic MS/MS spectra and improve 
N-terminal enrichment.  
3.3 MATERIALS AND METHODS 
3.3.1 Materials  
E. coli cell lysate was obtained from McLab (San Francisco, CA in USA). 
Bovine serum albumin (BSA), 4-sulfophenyl isothiocyanate, dithiothreitol and 
iodoacetamide were purchased from Sigma Aldrich (St. Louis, MO in USA). 
Trypsin Gold (mass spectrometry grade) was obtained from Promega (Madison, 
WI in USA), whereas the Zeba spin desalting column (7K MWCO) was from 
Pierce Biotechnology(Rockford, IL in USA) 
3.3.2 Protein denaturation, reduction and alkylation 
Sample, consisting of either 100 µg of BSA or 500 µg of E. coli cell lysate 
was dissolved to 5 mg/mL in 6 M urea and 20 mM sodium phosphate buffer (pH 
8). 50 mM dithiothreitol (DTT) was used to reduce disulfide bonds by incubating 
for 1 hr at 37 °C. Free sulfhydryls were alkylated with 50 mM iodoacetamide 
(IAM) at 25°C for 30 min. The unreacted IAM was quenched with DTT.   
3.3.3 Guanidination 
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The guanidination kit was obtained from Sigma-Aldrich. An o-
methylisourea hemisulfate solution was prepared at 6 mg/mL in water. The protein 
solution was adjusted to pH 10 by addition of NaOH (1 N) and a 100-fold molar 
excess of o-methylisourea hemisulfate was added. The mixture was then incubated 
at 65 °C for 30 min. The reaction was quenched by formic acid addition to pH 3.   
3.3.4 SPITC modification of N-termini 
A solution of SPITC was freshly prepared at 50 mg/mL in 20 mM sodium 
bicarbonate buffer (pH 9). The guanidinated protein mixture was adjusted to pH 9 
by addition of NaOH (1N). A 100-fold molar excess of SPITC was added to the 
mixture.  The mixture was then incubated at 65 °C for 1 hr.  
A Zeba spin desalting column (7K MWCO) was used to clean the sample. 
Briefly, the spin column was buffer exchanged with 50 mM ammonium acetate by 
centrifuging four times at 1500 g for one min.  A 130 µL aliquot of the sample was 
applied on top of the compact resin bed and centrifuged at 1500 g for 2 min to 
collect the sample.   
3.3.5 Trypsin digestion 
Trypsin was added to the buffer exchanged sample at an enzyme : substrate 
ratio of 1:50, and the sample was then incubated at 37 °C overnight. The reaction 
was quenched with addition of formic acid to a pH of 2 to 3. To prepare for ERLIC 
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injection, acetonitrile was added to the sample to reach 70% acetonitrile in the final 
solution.  
3.3.6 N-terminal enrichment by ERLIC 
An Agilent 1200 HPLC system, and a PolyWAX LP, 5-µm, 300 A, 2.1mm x 
50cm (Poly LC Inc., Columbia, MD) column were used for ERLIC. The stationary 
phase consists of a silica-based material with an adsorbed, cross-linked coating of 
linear polyethyleneimine. The flow rate was 300 µL/min and the column 
temperature was 25 °C. The UV detection wavelengths were set to 215 nm and 280 
nm. Mobile phase A was 20 mM ammonium formate, pH 2.2, with 70% 
acetonitrile. Mobile phase B was 900 mM ammonium formate, pH 2.2, with 10% 
acetonitrile. The column was used in a solid phase extraction fashion and only two 
fractions were collected. Therefore, 100% A was applied at the beginning for 3 
minutes to obtain the first fraction. Then, the mobile phase was switched to 100% 
mobile phase B with a one minute gradient and held for 10 minutes to obtain the 
second fraction. The first fraction (the flow through) predominately contained 
neutral and positively charged peptides; the second fraction is enriched in SPITC 
labeled peptides and other negatively charged peptides. Both fractions were dried 
using a SpeedVac evaporator (Thermo Electron) and then re-dissolved with 30 µL 
of water and subjected to LC-MS/MS analysis or stored at -20 °C for further 
analysis.  
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3.3.7 LC-MS/MS analysis 
LC-MS/MS was performed on a Dionex RSLC nano system (Thermo 
Scientific, San Jose, CA) coupled to a Q Exactive orbitrap mass spectrometer 
(Thermo Scientific, San Jose, CA).  An Easy Spray column from Thermo 
Scientific (50 cm* 75 µm, pepmap C18, 2 µm particle) was used with mobile 
phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in 
acetonitrile). Peptides were eluted over 180 min by linearly increasing mobile 
phase B from 0 to 30%. Mass spectrometry data were acquired automatically using 
Xcalibur software (Thermo Scientific) in data dependent acquisitions, with both 
survey scans and MS2 scans in the FT mode (resolution set at 35000 for parent 
ions and 17500 for fragment ions). Each survey scan was followed by 12 MS/MS 
scans. MS/MS spectra were acquired in the HCD mode using a normalized 
collision energy (NCE) of 25.  
3.3.8 Peptide identification 
Peptides were identified using the Thermo Proteome Discovery 1.3 software 
package (Thermo Scientific). Peptide and protein identifications were obtained 
using Sequest and Mascot algorithms. The E. coli K12 strain database prepared in 
a fashion similar to that described by Dormeyer et al14 was used for searching. 
Specifically, all protein sequences in the database were cut at arginines, and for 
each resulting peptide, multiple sequence database entries were generated that 
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represented sequential truncations of N-terminal amino acids.  Only sequences 6 
amino acids or longer were retained in the database.  Mass tolerance for parent ions 
was set to 10 ppm and 0.1 Dalton for fragment ions. Trypsin cleavage only at 
arginine residues was applied with up to 1 missed cleavage in the search. 
Carboamidomethylation of cysteine (+57.021Da) was set as a static modification. 
Dynamic modification included guanidination for lysine (+42.022 Da) and  N-
terminal or (to account for incomplete guanidination) lysine modification with 
SPITC (+215.971Da).  Percolator®, embedded in the proteome discovery software 
package, was used for peptide filtering, with a peptide false discovery rate (FDR) 
threshold set to 0.01.  
3.4 RESULTS AND DISCUSSION 
The strategy of the developed method was to first convert lysine to 
homoarginine by guanidination. In a second step, N-termini were sulfonated with 
4-sulfophenyl isothiocyanate (SPITC), thus permitting enrichment based on the 
newly acquired N-terminal negative charge. The downstream analysis strategy was 
to employ HCD activation for ion dissociation, coupled with high resolution 
MS/MS acquisitions.  
3.4.1 Overall workflow description 
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As depicted in the flow diagram in Figure 1, proteins were first denatured, 
reduced and alkylated. Prepared proteins were then subjected to guanidination 
resulting in conversion of lysine residues to homoarginine. Afterwards N-termini 
were sulfonated by reaction with 4-sulfophenyl isothiocyanate (SPITC), which has 
been shown to be useful for a variety of proteome applications. 22-24 Following 
trypsin digestion, SPITC modified N-terminal peptides were enriched by 
electrostatic repulsion hydrophilic interaction (ERLIC) chromatography. Both the 
flow-through fraction (containing predominantly internal and C-terminal peptides) 
and eluted fraction (enriched for SPTIC modified N-terminal peptides) were 
analyzed by LC-MS/MS.  
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Figure 3.1 Flow chart for N-terminal identification by SPITC modification 
and ERLIC enrichment. 
The above described derivatization procedure offers several advantages. 
First, 4-sulfophenyl isothiocyanate (SPITC) introduces a negatively charged 
sulfonic acid group to the N-teruminus. Upon dissociation, the negative charge 
neutralizes N-terminal ions (a and b ions), thereby promoting the generation and 
survival of C-terminal ions (y ions).  Therefore, the overall effect of SPITC 
Proteome
Denaturation, Reduction, 
and Alkylation
SEQUEST & MASCOT
database search, Percolator 
filtering
Guanidination of Lysine 
SPITC reaction with protein 
N-termini
Trypsin Digestion
N-terminal peptide 
enrichment by ERLIC
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derivatization is to improve tandem mass spectra by generating predominantly y-
type ions. An additional benefit is that often the [b1 + SPITC] product ion is 
present, which confirms that modification of the N-terminus had indeed occurred. 
These spectral features/characteristics increase confidence in identifying N-
terminal peptides and allow discrimination between SPITC derivatization 
occurring at the desired N-terminus position from those potentially occurring at 
lysine side-chains.  
A second advantage of SPITC derivatization is that the negative charge 
obtained upon sulfonylation allows differentiation of N-terminal peptides from 
other peptides in the mixture, and therefore can be used to selectively enrich N-
terminal peptides. ERLIC enrichment entails N-terminal peptides retention on the 
column due to hydrophilic interaction and electrostatic attraction, while all the 
other peptides elute at close to the void volume due to electrostatic repulsion.  
A third advantages related to the guanidination reaction that the positive 
charge from lysine is retained, thus preserving solubility and ionization efficiency. 
The guanidination reaction converts lysine to homoarginine, conserving the 
positive charge, as opposed to other chemical modifications such as dimethylation 
or acetylation where the side chain of lysine is converted to an uncharged group. 
The guanidination reaction increases the basicity of lysine thus promoting the 
solubility of denatured proteins, and increasing the charged character of the 
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peptides which leads to improved ionization efficiency. The relatively high 
solubility of these modified proteins in mild buffer solutions facilitates clean-up 
prior to trypsin digestion.  In the current protocol, excess reagent was removed and 
buffer was exchanged directly to the trypsin digestion buffer (50 mM ammonium 
acetate) by Zeba Spin desalting column (7K MWCO) in 10 min.  
A fourth advantage of the combination of guanidination and SPITC 
derivatization in terms of streamlining the workflow is that the modification 
reactions are relatively rapid, as it takes 30 min to complete the guanidination 
reaction, and one hour to finish the SPITC modification. This time scale is 
comparable to that of the acetylation reaction (2h), but much shorter than the 
dimethylation reaction (overnight).  In addition, there is no need for clean-up until 
all the reactions are completed, because any excess reagent from one step does not 
interfere with the next step.  
Lastly, the current workflow obviates more laborious procedures such as 
protein precipitation and peptide desalting, making it more convenient for higher 
sample throughput. Instead of precipitating proteins, Zeba Spin desalting columns 
(7K MWCO) were used to clean up samples, enabling numerous samples to be 
processed in 10 min using a centrifuge. 
3.4.2  Chemical modification of free amine groups in proteins 
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After denaturing, reduction and alkylation of sulfuryl groups in proteins, the 
free amine groups were modified by a stepwise procedure. First, selective 
modification was performed on the ε-amine of the side chain of lysine to convert 
lysine to homoarginine (the reaction is shown in Figure 3.2). It has been reported 
that the reaction can be completed in approximately 5 min, because after this time 
interval, no signals from unguanidinated-lysine containing peptides were observed 
by MALDI-MS.19 The reaction efficiency of this reaction was tested using the 
model peptide TNEIVEEQYTPQSLATLESVFQELGK and it was found by LC-
ESI-MS that the reaction proceeded to approximately 90% completion under 
optimum conditions. After guanidination, SPITC modification (Figure 3.3) was 
performed. Using the peptide AAAAK as a model compound, SPITC modification 
proceeded to 100% completion upon incubating at 65 °C for one hour with 20 mM 
sodium bicarbonate as buffer. 
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Figure 3.2 Schematic illustration for the guanidination reaction 
 
 
 
 
 
 
Figure 3.3 Schematic illustration of SPITC modification 
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3.4.3 Trypsin digestion specificity after guanidination 
Upon guanidination, lysine was converted to homoarginine. The selectivity 
of trypsin digestion at homoarginine was evaluated using BSA. As expected, the 
cleavage capacity at the now modified lysine was dramatically reduced. Taking the 
N-terminal peptide of BSA as an example, the sequence for zero missed cleavages 
is DTHK (m/z 757.2 +, lysine converted to homoarginine, N-terminus modified by 
SPITC), the sequence for one missed cleavage is DTHKSEIAHR (m/z 725.8 2+ and 
484.2 3+; lysine converted to homoarginine; N-terminus modified by SPITC). The 
ratio of the peak area (the combination of doubly and triple charged peaks) in the 
extracted ion chromatogram for the one missed cleavage product versus the area 
for the zero missed cleavage product was 116 : 1.  In a control sample, trypsin 
digestion for BSA without guanidination indicated that the peak area ratio for the 
same pair was 0.45 : 1. The conversion of lysine to homoarginine therefore 
hindered the trypsin activity on this site, and the majority of trypsin digested 
product of guanidinated protein resulted in peptides ending with arginine at the C-
termini.  
3.4.4 Effectiveness of N-terminal enrichment  
The SPITC modification introduces a sulfonic acid group to N-terminal 
peptides which remains negatively charged even at low pH. We viewed 
enrichment/purification of these sulfonated N-terminal peptides by ERLIC as an 
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attractive strategy based on reports that tryptic peptides containing only one 
phosphate can be separated from peptides with no phosphates20. In our approach, 
an anion exchange column is essentially used in hydrophilic mode. At pH 2.2, 
basic amino acids and the primary amines of N-termini possess positive charges, 
the carboxylic acid sites at C-termini and on glutamic acid and aspartic acid side 
chains are neutral. Phosphate groups, however, are negatively charged. Thus, by 
operating in the hydrophilic mode, the hydrophilicity of phosphate groups together 
with their electrostatic attraction to positively charged sites on the stationary phase 
overcomes the electrostatic repulsion experienced by protonated amino acid sites 
on the peptides, and allows separation of phosphopeptides from peptides without 
such anionic groups. We reasoned that SPITC peptides (bearing sulfonate groups) 
will interact similarly with the stationary phase as peptides with single phosphate 
groups. However, since phosphorylated peptides are generally present in much 
lower abundances than N-terminal peptides, their interference should be minimal 
when attempting to identify N-terminal peptides. To our knowledge, this is the first 
application of the ERLIC technique for sulfated peptide enrichment from non-
sulfated peptides, and the approach could prove to be useful for analyzing 
important post-translational modifications such as tyrosine sulfation.  
Another aspect worth mentioning concerning ERLIC is that an ammonium 
formate based mobile phase system was used, which simplifies sample clean-up. 
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For each ERLIC analysis, two fractions were collected. The first fraction contained 
the internal and C-terminal peptides, which were positively charged at pH 2.2 and 
were repelled from the column, and thus eluted with the void volume. It is 
reasonable to expect much higher absorbance from the first fraction than from the 
second fraction, since the N-termini only constitute a small portion of the peptide 
pool. We did observe a large absorbance at 215 nm for the first fraction; however, 
the high concentration of ammonium formate (900 mM) skewed the UV 
absorbance reading at 215 nm and no quantitative data was obtainable in terms of 
the ratio of these fractions. Due to the presence of the benzyl group introduced by 
SPITC derivatization, a high UV absorbance at 280 nm was observed for the 
second fraction, demonstrating that these peptides are enriched with SPITC 
peptides as shown in Figure 3.4. Additional comparisons can be found in the 
section describing peptide identification results below. 
Another benefit of ERLIC enrichment was that the internal peptides and C-
terminal peptides were preserved, thus allowing their analysis by LC-MS/MS. The 
obtained information can serve as cross-validation of the N-termini detected from 
the SPITC fraction. The correlation between fraction 1 and fraction 2 helps address 
the “one-hit wonder” problem in positional proteomics. Examples are provided in 
subsequent sections below.  
 
  
Figure 3.4 Fraction collections for trypsin digested 
electrostatic repulsion hydrophilic interaction (ERLIC) chromatography; (A) 
UV detection at 215 nm and (B) UV detection at 280 nm.
 
3.4.5 Tandem mass spectra comparison between CID and HCD
To assess the differences in fragmentation
spectra from multiply charged ions of SPITC modified peptides were 
CID using an LTQ OrbiTrap XL and 
spectra of the BSA N-terminal peptide
Figure 3. Upon CID dissociation, several y ions were generated as marked in 
Figure 3.5a. In comparison, HCD dissociation yielded a much higher quality 
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 patterns between CID and HCD, 
to HCD using a Q Exactive. Dissociation 
 acquired by CID and HCD are shown 
 
 
 
subjected to 
in 
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tandem mass spectrum (Figure 3.5b), composed of a complete set of y fragment 
ions. The only significant N-terminal fragment ion observed was b1 + SPTIC, 
which pinpoints the SPITC modification to the N-terminus. This process is 
proposed to be promoted by the nucleophilic sulfur atom of the SPITC moiety 
attacking the carbonyl oxygen atom of the adjacent amino acid, resulting in an 
Edman-type degradation.25,26 The lack of other N-terminal ions illustrate that 
SPTIC derivatization at the peptide N-termini can effectively neutralize the 
positive charge of the N-terminal ions (a and b ions) upon activation, thus yielding 
spectra rich in y ions for peptide sequencing. Besides improving spectral quality, 
the generation of high mass accuracy fragment ions is another positive attribute of 
HCD on the Q Exactive Orbitrap. This improved mass accuracy of fragment ions 
improves confidence in peptide filtering via the semi-machine learning Percolator 
algorithm. 
 
 
 
 
 
 
  
 
Figure 3.5 MS/MS spectra for BSA peptide SPITC
DTHK(guandinyl)SEIAHR   m/z= 484.20
is attached to N
 
3.4.6 N-termini analysis of E. coli cell lysate
The workflow as described above was applied to an 
Sample preparation followed by LC
and the results reported below represent pooled
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3+
 by (A) CID and (B) HCD. SPITC 
-terminal ions labeled in red. 
 
E. coli
-MS/MS analysis was performed in triplicate 
 data acquired from the three runs.  
  
 cell lysate. 
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A total of 358 N-terminal SPITC-labeled high confidence peptides were identified 
in the bound fraction with a false discovery rate (FDR) less than 0.01 (assessed by 
Percolator). These peptides represented 274 proteins annotated in the E. coli 
database. We found that the presence and location of guanidinyl lysine 
(homoarginine) played an important role in terms of the appearance of MS/MS 
spectra, with higher quality MS/MS spectra obtained for peptides without 
guanidinyl lysine.  For those N-terminal peptides without guanidinyl lysine, the 
MS/MS spectra were dramatically simplified and were composed of predominately 
y-type ion series, as shown in Figure 3.6. There were 315 cases belonging to the 
category of those 358 high confidence N-terminal SPITC labeled peptides. The 
remaining 43 peptides contained guanidinyl lysine, and the peptide fragmentation 
profile changed case-by-case as shown in Figure 3.7. The spectra contained both y 
and b ions for sequence VVINK(guanidinyl) and DTTTIIDGVGEEAAIQGR as 
labeled in Figure 3.7a, the possible explanation might be that homoarginine located 
towards the N-terminal side of peptide may aid in the survival of b ions. Whereas 
the spectra contained predominately the y-ion series for peptide sequence 
LDMLNEELSDK (guanidinyl)ER .  
 
 
 
  
 
Figure 3.6 MS/MS spectra for N
(A) sequence MNIIEANVATPDAR, M1
dimethyl-8-ribityllumazine synthase OS=
AVTNVAELNALVER, A2
dehydrogenase OS=Escherichia coli
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-terminal peptides without guanidinyl lysine; 
-SPITC  protein ID P61714 (6,7
Escherichia coli) and (B) sequence 
-SPITC protein ID P0A9Q7 ( Aldehyde
). SPITC is attached to N-terminal ions 
labeled in red. 
 
-
-alcohol 
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Figure 3.7 MS/MS spectra of N-terminal peptide containing guanidinyl lysine; 
(A) VVINK(guanidinyl) DTTTIIDGVGEEAAIQGR  protein ID P0A6F5 (60 
kDa chaperonin OS=Escherichia coli ) and (B) LDMLNEELSDK 
(guanidinyl)ER   protein ID P63284(Chaperone protein ClpB OS=Escherichia 
coli). SPITC is attached to N-terminal ions labeled in red. 
 
There were occasions, however, when two sequences were identified for the 
same peptide species, the difference being that one had a guanidinyl lysine and the 
other had an unmodified lysine (see Figure 3.8). Both peptide species were 
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modified at the N-termini by SPITC. The y-ion series in both spectra showed 
similar patterns and intensities up to the y11 ion (just after lysine). For the 
guanidinyl modified peptide, no further y ions were detected, while for the peptide 
with no lysine modification, y12, y13, y14 and y15 were also present in the MS/MS 
spectra.  The assignments of y12 to y15 were valuable since this clarified that the 
SPITC modification occurred at the N-termini, not at the lysine, whose side-chain 
failed to be modified by the guanidination reaction.  
 
  
 
Figure 3.8 MS/MS spectra for SPITC peptide ELVTAAKLGGGDPDANPR 
(protein ID P0A8A0; (A) containing unmodified lysine and (B) containing 
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guanidinyl Lysine. 
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A detailed analysis of the data showed that a single protein may present 
multiple N-termini. This may sound counter-intuitive, but cellular systems are 
complex with the coexistence of various enzymes, which can decompose proteins. 
One example is given for protein P0A850 (Trigger factor OS=Escherichia coli), in 
which three N-termini were observed with high confidence by our approach. The 
three peptides were P0A850from1to13, P0A850from244to255 and 
P0A850from322to334. The annotated peptide (1-13) was in low abundance 
compared to the other two peptides, judging by PSMs (a higher number correlates 
with higher abundance; PSMs for AA1-13 is 1, while PSMs for the other peptides 
are 5). In addition, the assignment of N-termini can be assured by the quality of 
each spectrum. The spectral simplification effect of the SPITC modification was 
present in all three N-termini of P0A850 as depicted in Figure 3.9. Therefore, we 
conclude that all these three peptides are N-terminal peptides derived from protein 
P0A850.  
 
 
 
 
  
Figure 3.9 MS/MS spectra for N
factor OS=Escherichia coli); (A) P0A850from1to13, (B) P0A850from244to255, 
and (C) P0A850from322to334. SPITC is attached to N
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3.4.7 Comparison of bound and flow-through fractions of E. coli cell 
lysate 
As we described previously, the chemically-modified protein digest was 
fractionated into two parts. One fraction was unbound with ERLIC and the other 
was bound with ERLIC (N-terminal enriched). The unbound fraction was also 
collected and the identified proteins were used to examine the crossover with the 
identified N-terminal peptides. Three sample preparations followed by LC-MS/MS 
analyses were performed for the E. coli cell lysate using the described workflow. 
The findings reported below represent pooled results of peptide identification for 
these data. 
Table 3.1 presents counts and percentages of peptides (and corresponding 
PSMs) determined to be labeled with SPITC (on N-termini and lysines) found in 
both the bound and flow-through fractions.  Consistent with the observations 
reported above on the basis of UV absorbance, the overall intensity of the signal is 
~3-4x higher in the flow-through fraction as compared to the one bound to ERLIC.  
At the same time relative enrichment for N-terminal SPITC tagged peptides is 
about 10x higher in the ERLIC bound fraction as compared to that in the flow-
through (e.g. 14% of peptides in bound fraction were identified as SPITC labeled 
at N-termini as compared to ~1% in the flow-through fraction).  Similar 
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observations can be made on the basis of PSM counts, which are approximate 
indicators of peptide abundance in the mixture – those determined to be labeled 
with SPITC at the N-terminal account for about 10% of the total PSM count in the 
bound fraction versus ~1% in the flow-through fraction. 
Table 3.1 Counts and percentages of peptides and corresponding PSMs 
annotated as labeled with SPITC (on N-termini and lysines) and not in bound 
and flow-through fractions of E. coli cell lysate. 
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 Peptides: PSMs: 
 Lysines N-Term Other Lysines N-Term Other 
Bound 301 (11%) 358 (14%) 1965 (75%) 949 (12%) 918 (11%) 6358 (77%) 
Flowthro
ugh 
124 (2%) 108 (1%) 7270 (97%) 216 (1%) 164 (1%) 23462 (98%) 
 
 
 The pie chart for calculated pI of identified peptides for bound and unbound 
fractions are shown in Figure 3.10. The bound fraction (A) contains mostly acidic 
peptides; since 71% of the peptide population is composed of peptides with pI 
lower than 4.99, with 10% contributed by pI lower than 3.99 and 61% by pI 
between 4-4.99. The unbound fraction (B) shows 38% of peptides with pI lower 
than 4.99, with only 1% from peptides with pI lower than 3.99. This agrees well 
with the ERLIC theory that acidic peptides have weaker electrostatic repulsion 
relative to the basic peptides, and they therefore exhibit higher retention on the 
column.  
 
 Figure 3.10 pie chart for calculated pI of identified peptides for (A) bound fraction and (B)  
unbound fraction 
 
Figure 3.11 shows the
flow-through and bound fractions.  The majority of the proteins detected in the 
bound fraction irrespective of their SPITC labeling status were also detected in the 
flow-through fraction. Similarly, the majority (~80%) of the proteins iden
labeled with SPITC on the N
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 overlaps between identified proteins detected in the 
-termini were also detected in the flow
tified as 
-through 
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fractions with peptides lacking the SPITC label. Proteins identified both in flow-
through fractions and by N-terminal SPITC labeled peptides in the bound fraction 
tend to have higher PSM counts indicative of their higher abundances as compared 
to those that were present only in one of these two sets (Figure 3.12). Comparison 
of the peptides identified in the flow-through and bound fractions provides an 
additional level of support for the reliability of detection of the enriched N-
terminal SPITC labeled peptides in the bound fraction. 
 
 
 
 
Figure 3.11 Overlaps between protein accessions identified in flow-through 
and bound fractions; (A) all proteins identified in each of the fractions and (B) 
all proteins identified in flow-through fractions versus those detected in bound 
80 
 
fraction as labeled with SPITC on N-termini.  Areas are approximately 
proportional to the counts shown in the figures. 
 
 
 
 
Figure 3.7 Sums of PSMs for all proteins (A) in flow-through fraction and (B) 
those in bound fraction that were identified as N-terminal SPITC labeled. In 
each case, proteins were split into two groups those that were also present in 
the other set (N-terminal SPITC in bound fraction or all proteins in flow-
through fraction respectively) or only present in the given set.  Proteins 
present in both sets tend to have higher PSM sums, suggesting their higher 
abundance. 
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 3.5 CONCLUSIONS 
The method presented herein shows many improvements over existing 
positional proteomics approaches.  The use of SPITC modification at the N-termini 
enables the generation of high quality MS/MS spectra for high fidelity 
assignments, and enrichment due to the addition of the negatively-charged sulfate 
group. The ERLIC separation was advantageous compared to free amine 
scavenging approaches, due to the lower losses and the isolation of internal and C-
terminal peptides for cross-validation of N-terminal assignments.   
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Chapter 4  iTRAQ Labeling of N-terminal Amines in Complex 
Samples and Its Application in Protease Substrate Degradomics 
4.1 Abstract 
A positional proteomics strategy for proteolytic cleavage sites is presented 
based on iTRAQ labeling at the N-termini of peptides followed by enrichment on a 
NHS-activated agarose spin column. After substrates are treated with protease, a 
guanidination reaction is used to block the primary amine of the lysine side chain; 
subsequent reaction with iTRAQ reagents labels only the primary amine of the N-
termini. A control sample is prepared following the same steps, except that there is 
no protease treatment. All iTRAQ labeled samples are then pooled and treated with 
trypsin. The newly trypsin-digested sample is a mixture of peptides of various 
characteristics: N-terminal peptides (N-termini capped with iTRAQ reagent), 
internal peptides (free N-termini and Arg as C-termini) and C-terminal peptides 
(free N-termini). The latter two portions, which contain primary amines at the N-
termini, can be scavenged by NHS-activated agarose beads, resulting in 
enrichment of iTRAQ labeled peptides. Samples prepared in this manner are 
subjected to LC-MS/MS analysis and database searching, thus, the substrate of the 
protease can be revealed. Since the N-termini of protease cleavage are preserved 
by iTRAQ labeling, the proteomic scale analysis of N-termini will disclose the 
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cleavage sites of protease. In this report, Asp-N digested E.coli cell lysate is taken 
as a model system. A total of 764 N-terminal peptides, corresponding to 377 
proteins, are identified in one experiment, with 91% of those proteolytic products 
matching the expected protease digestion specificity. Our results suggest that 
iTRAQ in combination with N-terminal proteomics is useful for the identification 
of the proteolytic cleavage sites in complex systems as well as for the 
establishment of an in vivo proteolytic signature profile.  
 
4.2 Introduction 
The majority of proteomics studies appearing in the recent literature employ 
a “shotgun” approach,1-3 where the proteins are first digested into peptides, 
typically using trypsin as protease, that are subsequently analyzed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Proteome systems 
typically encompass thousands of individual components present in different 
concentrations varying over several orders of magnitude.4 This poses a major 
challenge to achieving high proteome coverage even when employing highly 
advanced instrumentation and workflows. Positional proteomics5-7 has drawn 
attention to the concept that a single peptide with a well-defined position (typically 
N-terminal or C-terminal) can be used to characterize the entire protein. Using this 
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principle, the sample complexity can be drastically decreased and the recovery, 
especially for low abundant proteins, is expected to increase. N-terminal positional 
proteomics has found value in another subfield of proteomics called degradomics8-9 
that focuses on identifying proteases and their corresponding substrates. In the 
human genome, 570 genes are predicted to encode for proteases. The substrates for 
half of those proteases are unknown, while processing of known targets of the 
other half is not well characterized.10 To fully understand the physiological and 
pathological implications of proteases, identifying their substrates and cleavage 
sites is a first step forward in this unknown territory. N-terminal positional 
proteomics has been shown to be a valuable tool in this field.11-13 
The essence of positional proteomics lies in the ability to differentiate 
selected positional peptides from other redundant peptides via the use of chemical 
or enzymatic modification. The relatively high reactivity of the N-terminal primary 
amine compared to the less reactive C-terminal carboxylic acid is a major reason 
that the numbers of N-terminal proteomics reports far exceed those of the latter in 
this subfield of proteomics.  Due to the robustness and simplicity of reaction, as 
well as the availability of isotopic forms of reagents, the most widely used 
chemical modifications in N-terminal proteomics are dimethylation14-15 and 
acetylation16-17. In dimethylation, catalyzed by sodium cyanoborohydride, 
formaldehyde is used to simultaneously label all free amino groups, i.e., the 
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primary amine of lysine, as well as those of each N-terminus. In-solution, online 
and on-column protocols for stable isotope dimethyl labeling were described in 
detail by Boersema et al15 for sample amounts ranging from sub-micrograms up to 
milligrams. An example of acetylation was described by McDonald et al16 
employing sulfo-NHS acetate. Similar to the dimethylation reaction, acetylation 
blocks all primary amines in peptides and proteins.  
Isobaric tagging for relative and absolute quantitation (iTRAQ) labeling is a 
useful tool in protein biomarker expression analysis.18-20 The reagent consists of a 
reporter group, a balance group and an amino reactive group, enabling isotopic 
arrangement that permits 4-plex or 8-plex reagents. The unique feature of the 
iTRAQ reagent is that peptides labeled with different reagents have the same 
nominal mass, while upon MS/MS, each individual label produces an exclusive 
reporter ion, which permits relative quantitation of the peptide(s) in each sample. 
Changes in biomarker levels are observable in the peptide reporter ions generated 
by MS/MS, thus allowing one to pinpoint the relevant proteins.   
A strategy using iTRAQ as the labeling reagent in N-terminal proteomics is 
explored in this study.  iTRAQ is used for two purposes; firstly, to serve as tagging 
reagent to differentiate N-terminal peptides from internal peptides, and secondly, 
to provide direct verification for N-terminal peptides when duplicate samples are 
tagged with different iTRAQ labels.   
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4.3 Experiment 
4.3.1 Materials  
E. coli cell lysate was obtained from McLab (San Francisco, CA in USA). 
Guanidination kit, dithiothreitol (DTT) and iodoacetamide (IAM) were purchased 
from Sigma Aldrich (St. Louis, MO in USA). iTRAQ 4-plex was obtained from 
Applied Biosystems (Framingham, MA in USA). Trypsin Gold (mass spectrometry 
grade) was obtained from Promega (Madison, WI in USA). Endoproteinase Asp-N 
(sequencing grade) was purchased from Roche (Indianapolis, IL in USA). Zeba 
spin desalting column (7K MWCO) and the NHS-activated agarose spin column 
were obtained from Pierce Biotechnology (Rockford, IL in USA).  
4.3.2 Reduction and alkylation 
2 mg of E. coli cell lysate was dissolved with 200 µL of Urea (6 M, with 0.1 
M phosphate buffer, pH 7.5). The solution was incubated at 37 °C for 30 min. A 40 
µL aliquot of DTT (0.5M) was added and the mixture was incubated at 37 °C for 
30 min. A 100 µL aliquot of IAM (0.5 M) was added and the sample was 
incubated at room temperature in the dark for 30 min. Another 10 µL aliquot of 
DTT was added to quench the alkylation reaction.  
4.3.3 Guanidination  
90 
 
The guanidination kit was obtained from Sigma-Aldrich.  The concentration 
of o-methylisourea hemisulfate was prepared at 6 mg/mL in water. The protein 
sample was adjusted to pH 10 by NaOH (1N) after reduction and alkylation and 
100-fold molar excess of o-methylisourea hemisulfate was added. The mixture was 
then incubated at 65 °C for 30 min.  
A 50 µL aliquot of urea (6M at pH 7.5) was added to make a 5 mg/mL 
protein solution. A Zeba spin desalting column was first buffer exchanged with 
100 mM sodium phosphate buffer (pH 7.5) (300 µL of buffer each time, spin down 
for 1 min at 1000 g, 4 times in total for each spin column).  Two separate Zeba 
spin columns were used, with each loaded with 120 µL of protein sample. The 
flow-through of one sample was used for Asp-N digestion, while the flow-through 
of the other was labeled with iTRAQ directly as a control.  
4.3.4 AspN-digestion 
6 µg of endoproteinase Asp-N was dissolved in 120 µL of water. The 
enzyme was mixed with 60 µg of cell lysate (after guanidination and Zeba spin 
desalting clean-up), and the mixture was incubated at 37 °C for 18 h. The sample 
was freeze-dried prior to iTRAQ labeling.  
4.3.5 iTRAQ labeling 
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Two 25 µg control portions of cell lysate (after guanidination and Zeba spin 
desalting clean-up) were each diluted with 20 µL of urea (6M, with 0.1 M 
phosphate buffer, pH 8.5) in separate vials.  Each cell lysate vial was mixed with 
the iTRAQ reagent dissolved in 70 µL ethanol; one vial was reacted with iTRAQ 
tag 114 and the other with iTRAQ tag 115. The mixture was incubated for 2 hr at 
room temperature.   
Two replicates of 25 µg of AspN digested cell lysate were each diluted with 
20 µL of phosphate buffer (pH 8.5) in separate vials.  Each digested sample vial 
was mixed with the iTRAQ reagent dissolved in 70 µL ethanol; one vial was 
reacted with iTRAQ tag 116 and the other with iTRAQ tag 117. The mixture was 
incubated for 2 hr at room temperature.    
All the iTRAQ labeled samples were pooled into a single vial and dried by 
centrifuging. The sample was re-suspended in 196 µL of sodium bicarbonate (0.1 
M).  
4.3.6 Trypsin digestion 
4 µg of trypsin (1 µg/µL in water) was added to the pooled iTRAQ solution. 
The solution was incubated at 37 °C overnight.  
4.3.7 N-terminal enrichment by NHS-activated agarose resin 
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PBS buffer (200 µL, 0.1 M sodium phosphate and 0.3 M sodium chloride, 
pH 7.2) was added to the trypsin-digested solution, which was directly added to 
NHS-activated agarose dry resin. After mixing the sample end over end for 1 hr, 
the spin column was centrifuged at 1000 g for 1 min and the flow through was 
collected; this flow-through contained the N-termini enriched portion. The resin 
was further washed twice with 400 µL of PBS buffer, with collection of the flow 
through. These three flow-through portions were combined and desalted by C18 
cartridge. The salt was washed out with 0.1% formic acid in water and the N-
terminal peptides were eluted with 0.1% formic acid in 80% acetonitrile in water. 
After drying the solvent by centrifuge, the N-terminal peptides were re-dissolved 
with 40 µL of water and subjected to immediate LC-MS/MS analysis or stored at 
−20 °C for further analysis.  
4.3.8 LC-MS/MS  
LC-MS/MS was performed on a capillary Dionex U3000 HPLC system 
(Thermo Scientific, San Jose, CA) coupled to a QExactive Orbitrap mass 
spectrometer (Thermo Scientific, San Jose, CA).  A Targa C18 column from 
Higgins Analytics (150 cm* 300 µm, 3 µm particle) was used with mobile phase A 
(0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). 
Peptides were eluted over 90 min by increasing mobile phase B from 0 to 30% 
linearly. Mass spectrometry data were acquired automatically using Xcalibur 
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software (Thermo Scientific) in data dependent acquisitions, with both survey 
scans and MS2 scans in the FT mode (resolution set at 35000 for parent ions and 
17500 for fragment ions). Each survey scan was followed by 12 MS/MS scans. 
MS/MS spectra were acquired in HCD mode with normalized collision energy 
(NCE) of 25.  
Peptides were identified by the Thermo Proteome Discovery 1.3 software 
package (Thermo Scientific). Peptide and protein identifications were obtained 
using Sequest and Mascot algorithms. The E. coli K12 strain database prepared in 
a fashion similar to that described by Dormeyer et al23 was used for searching. 
Specifically, all protein sequences in the database were cut at arginine (C-
terminal); for each resulting peptide (i.e., the series of neo-N-terminal peptides 
created as a result of these cleavages), multiple sequence database entries were 
generated that represented sequential truncations of each N-terminal amino acids.  
Only sequences 6 amino acids or longer were retained in the database.  The mass 
tolerance for parent ions was set to be 10 ppm and 0.1 Dalton for fragment ions. 
Trypsin cleavage was applied with up to 1 missed cleavage in the search. 
Carboamidomethyl of cysteine (+57.021Da) was set as a static modification. 
Dynamic modification included guanidination for lysine (+42.022 Da) and N-
terminal modification with iTRAQ (+144.102 Da). Percolator (Thermo Scientific) 
was used for peptide filtering, with a peptide FDR threshold set to 0.01.  
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4.4 Results and Discussion 
Enoksson et al21 reported the identification of ten caspase-3 cleavage sites in 
a mixture of 7 purified recombinant E. coli proteins using iTRAQ, with all sites 
corresponding to caspase-3 previously reported cleavage sites.  Prudova et al.22 
incorporated iTRAQ whole protein labeling with terminal amine isotopic labeling 
(iTRAQ-TAILS) to enrich the N-terminome by negative selection. By this 
approach, substrate degradomes of two closely related matrix metalloproteinase 
MM2 and MM9 were found to be significantly different. We have employed Asp-
N digested E. coli cell lysate as a model system, where a protein database already 
exists and enzyme specificity is mostly known. Our results demonstrate that this 
combination of iTRAQ with N-Terminal proteomics can be used for the 
identification of the proteolytic cleavage sites in complex system and for the 
establishment of proteolytic signature profile in vivo.  
4.4.1 Strategy for the identification of N-terminal proteolytic peptides 
The strategy to identify N-terminal proteolytic peptides is illustrated in 
figure 4.1 using Asp-N as an example. The substrate was E. coli cell lysate. 
iTRAQ tags 114 and 115 were used to label the cell lysate sample, while iTRAQ 
tags 116 and 117 were used to label the Asp-N digested cell lysate sample. Prior to 
iTRAQ labeling, the side chain of lysine in both samples is blocked by the 
guanidination reaction.  After pooling iTRAQ labeled samples, trypsin digestion 
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was performed, followed by N-terminal enrichment employing a NHS agarose spin 
column. LC-MS/MS data was then acquired. In the current workflow, peptides can 
be identified as belonging to the protein N-termini if all four tags are visible in the 
mass spectrum, whereas the peptides originating from Asp-N cleavage will only 
appear with two tags (116 and 117).  Thus, peptides without the 116 and 117 labels 
most likely originate from internal peptides which survive the NHS-activated 
agarose enrichment process. Replicate samples with different tags allow 
simultaneous validation of identified peptides. Therefore, peptides with only one 
tag are ignored in the final peptide counting.  
 
 Figure 4.1 Scheme for N
 
4.4.2 E. coli cell lysate results using the proposed workflow
A total of 100 µg of 
with one quarter reacted with each iTRAQ tag. The samples were prepared 
according to the workflow as in figure 
Discovery 1.3 software (Thermo Scientific) 
then by modifications (containing N
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the confidence level of identification. A total of 500 N-terminal iTRAQ labeled 
peptides with E. coli protein accessions were identified with medium to high 
confidence.  These peptides represented 370 proteins found in the E. coli database.  
Endoproteinase Asp-N is known to cleave peptide bonds N-terminally at 
aspartic and cysteic acid.24-26 Ingrosso et al. reported that Asp-N can also cleave at 
glutamyl residues.27 Thus, the neo-N-terminal peptides produced by endoprotease 
digestion are expected to start predominately with Asp (D) and a lesser amount of 
Glu (E). Of those 764 N-termini iTRAQ peptides identified, 481 peptides had N-
terminal Asp. We also found 215 peptides with N-terminal Glu. Altogether, 
peptides starting with Asp and Glu account for 91% of N-terminal peptides 
identified. There are 6 peptides that start with methionine, and 17 peptides are 
identified as annotated peptide sequences obtained by stripping off the first 
methionine, thus, annotated protein N-termini account for 3% of peptides 
identified.  The origin of the other 6% is unclear.  
An example of the annotated N-terminal peptide is presented in Figure 4.2a. 
This peptide sequence is identified with high confidence to be iTRAQ-MFPEYR 
by Proteome Discovery. With MFPEYR as the N-terminal peptide, the 
corresponding protein is determined to be P0ACW6 (Uncharacterized protein 
YdcH OS=Escherichia coli). The inset of Figure 2a shows the four reporter ions, 
further validating that this peptide is not from Asp-N digestion.   
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An example of an Asp-N digested neo-N-terminal peptide is shown in 
Figure 4.2b. This peptide sequence is identified to be iTRAQ-DVQVFTR through 
software assignment of both b and y series ions. This peptide is determined to be 
the 930 to 936 heptamer in protein P0A8V2 (DNA-directed RNA polymerase 
subunit beta OS=Escherichia coli). As shown in the inset in Figure 2b, only two 
reporter ions (m/z 116, 117) are present for this peptide, validating that this peptide 
is the product of Asp-N digestion.  
 
 
 
 
 
 
 
 
 Figure 4.2 iTRAQ labeled N
protein P0ACW6 (Uncharacterized protein YdcH OS=
position 1-6     (b) iTRAQ
RNA polymerase subunit beta OS=
4.5 Summary 
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-terminal peptides (a) iTRAQ-MFPEYR  from 
Escherichia coli
-DVQVFTR from protein P0A8V2(DNA
Escherichia coli), position 930
 
 
), 
-directed 
-936. 
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An Asp-N digested E. coli cell lysate was employed as a model system to 
demonstrate the application of a novel workflow to study proteolytic cleavage sites 
and substrates. This workflow differentiates N-termini and neo-N-termini by 
iTRAQ, and enriches these species for improved sensitivity by negative selection 
using NHS agarose beads. A total of 764 N-terminal peptides were identified in 
one experiment, with 89% of those matching the protease digestion specificity. 
Those 764 peptides correspond to 377 proteins. Compared with dimethylation or 
acetylation modification, the obvious advantage of using iTRAQ as the labeling 
reagent is that 4 or 8 samples can be compared simultaneously with sensitivity 
improvement, which makes it an attractive approach for the establishment of in 
vivo proteolytic signatures.  
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Chapter 5 Summary 
The concept of positional proteomics is that a protein can be identified by a 
single, position-defined peptide, with the two most obvious positional locations 
within every protein being the N- and C-termini. The strength of positional 
proteomics arises from the dramatically reduced complexity of proteome samples, 
however, the strength turns into weakness in protein identification due to risks 
inherent in identifying a protein on the assignment of a single peptide’s 
fragmentation pattern, the so called “one hit wonder” problem. In this thesis, we 
focused on developing methods to identify peptides and proteins with higher 
confidence, by ensuring high quality spectra and/or utilizing internal validation.  
An approach was proposed where the N-termini fraction for positional 
proteomics from the peptide mixtures is enriched, while the rest of the peptide 
mixture is preserved. Therefore, MS analysis of the remaining peptide mixtures 
can serve as validation for the results of positional proteomics. In the process, 4-
sulfophenyl isothiocyanate (SPITC) is used to modify the N-termini and the SPITC 
modified peptides are separated from others using electrostatic repulsion 
hydrophilic interaction chromatography (ERLIC). Moreover, the confidence of N-
termini identification is further strengthened by exploiting the unique 
fragmentation behavior of SPITC peptides, thus we conclude that our approach 
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offers high fidelity assignment of N-terminal peptides. This work was presented in 
chapter 3.  
Another attempt to simultaneously validating the results of positional 
proteomics is to use iTRAQ to modify the peptide N-termini and this workflow 
was tested for its application to identify protease substrates. In this study, both 
control and protease treated sample were labeled by different tags, allowing direct 
comparison of protein N-termini with neo-N-termini. In addition, samples were 
analyzed in duplicate by labeling with two tags (e.g. tag 116 and tag 117), aiming 
for quick validation of peptides by internal replicates. Compared with 
dimethylation or acetylation modification, the dramatic advantage of using iTRAQ 
as labeling reagent is that up to 4 or 8 samples can be compared simultaneously 
with sensitivity improvement, which makes it an attractive approach for the 
establishment of proteolytic signatures in vivo. This work was presented in chapter 
4.  
The proof of concept of these approaches was demonstrated by application 
to  E. coli cell lysates. Further modification or workflow improvement may be 
needed for biological application. One limitation of the current workflow is that it 
will not detect proteins with N-terminal modifications such as acetylation or 
dimethylation, since SPITC only reacts with N-terminal amines. It is feasible to 
use an appropriate enzyme to treat the protein mixture prior to SPITC modification 
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in order to catch these protein N-termini.1 In addition, isotope labeled SPITC can 
be used for direct sample comparison.2  
Furthermore, it is common in proteomics applications to use of multiple 
enzymes for cleavage in order to improve protein coverage. 3 This approach is 
applicable here: instead of using only trypsin for digestion, the same sample can be 
treated with a combination of chymotrypsin, trypsin and/or Glu-C, thus improving 
the chances to produce peptides with the right sizes for high-fidelity MS 
assignment.  
Another application of the current concept is in the field of C-terminal 
proteomics. The negative charge introduced by SPITC at peptide N-termini, causes 
the neutralization of N-terminal ions (a and b ions) upon HCD, thereby promoting 
the generation and survival of C-terminal ions (y ions).  Therefore, the overall 
effect of SPITC derivatization is to improve tandem mass spectra by generating 
predominantly y-type ions. Similarly, study has shown that Lys-N digested 
peptides generate predominantly b ions in tandem mass spectra 4 . Thus, high 
fidelity for C-termini in proteomics scale should be achievable by incorporating 
Lys-N digestion. Such approach is going to be a valuable alternative for the 
currently under-utilized C-terminal proteomics.   
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Appendix 
 Appendix table 1 N-terminal peptides by SPITC modification 
sequence PSMs protein accessions Modification MH+(Da
) 
ADAQK 3 P0AES9from22to1
10 
N-Term(SPITC) 747.244
4 
ISQEVR 2 P30136from593to
598 
N-Term(SPITC) 946.379
6 
GQINIPEGR 1 P39321from1066t
o1074 
N-Term(SPITC) 1198.49
1 
KSDQNVR 8 P0A7L0from54to6
0 
N-Term(SPITC) 1061.41
4 
KTGNTPDGR 8 P09373from616to
624 
N-Term(SPITC) 1160.45 
QATKDAGR 7 P0A6Y8from152to
159 
N-Term(SPITC) 1061.41
6 
KPVNDLSR 12 P0A9M8from685t
o692 
N-Term(SPITC) 1143.49
8 
GLSAKSFDGR 18 P62399from116to
125 
N-Term(SPITC) 1252.50
6 
PWFIKALR 1 P33341from750to
757 
N-Term(SPITC) 1245.58
2 
SPDPFER 1 P37653from394to
400 
N-Term(SPITC) 1062.36
8 
EAAEQAKR 2 P0A705from135to
142 
N-Term(SPITC) 1117.44
6 
TFYAQLR 1 P75860from143to
149 
N-Term(SPITC) 1113.45
3 
MATKDGR 2 P65294from26to3
2 
N-Term(SPITC) 993.363 
VKLDEAGVR 4 P0AGE9from84to
118 
N-Term(SPITC) 1201.53 
KAPAEPQR 2 P0A9P0from256to
263 
N-Term(SPITC) 1111.46
5 
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sequence PSMs protein accessions Modification MH+(Da
) 
FTESEVISR 1 P75990from276to
284 
N-Term(SPITC) 1282.52
1 
LKNENPR 4 P0ACW6from12to
18 
N-Term(SPITC) 1085.45
6 
VMVLDIDEER 2 P0AG67from330t
o339 
N-Term(SPITC) 1433.56
7 
ENNAQTTNESAGQK 1 P0AFH8from29to
122 
N-Term(SPITC) 1706.64
4 
KAIGEAK 6 P0ABT2from134to
153 
N-Term(SPITC) 931.401
2 
VLIHPASLPEER 1 P28722from128to
139 
N-Term(SPITC) 1575.72
4 
LFLGVDAIDLER 2 P0ACK2from183to
194 
N-Term(SPITC) 1575.71
6 
VAEFFGKEPR 2 P0A6Y8from353to
362 
N-Term(SPITC) 1394.59
5 
VEQKVAR 5 P25553from337to
343 
N-Term(SPITC) 1044.46
4 
GIQPEEVER 1 P37353from361to
369 
N-Term(SPITC) 1271.50
4 
KLTETDQR 2 P0A7F3from34to4
1 
N-Term(SPITC) 1205.49
3 
AIQSEKAR 5 P0A7U7from11to
18 
N-Term(SPITC) 1117.47
9 
KLEAGDEVR 6 P0AA39from59to
67 
N-Term(SPITC) 1231.51
2 
VDALTNEVR 1 P30855from260to
268 
N-Term(SPITC) 1231.50
7 
PADAIDR 1 P76473from532to
538 
N-Term(SPITC) 972.357 
AVKAPGFGDR 1 P0A6F5from275to
284 
N-Term(SPITC) 1232.52 
TQQESLQKALR 1 P00968from390to
400 
N-Term(SPITC) 1516.69
5 
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sequence PSMs protein accessions Modification MH+(Da
) 
KSDNPSITR 8 P0A6H1from192t
o200 
N-Term(SPITC) 1232.50
8 
LLMEDLNDGLR 1 P09053from18to2
8 
N-Term(SPITC) 1503.61
9 
AIVKADNR 2 P0A6V8from201t
o208 
N-Term(SPITC) 1101.47
9 
TTQTVSGR 2 P0AGI1from2to9 N-Term(SPITC) 1064.41
5 
KPATAGMENR 4 P15288from59to6
8 
N-Term(SPITC) 1289.50
4 
AQNTAAYIGNGDR 3 P06996from226to
238 
N-Term(SPITC) 1565.61
1 
STIEER 7 P0A6A8from2to7 N-Term(SPITC) 949.341
3 
ELKDAGADR 2 P00968from427to
435 
N-Term(SPITC) 1189.46
3 
ILQNEDKR 1 P13035from247to
254 
N-Term(SPITC) 1230.52
3 
VDKDAVSR 7 P0A8M0from292t
o299 
N-Term(SPITC) 1104.44
8 
TSHVEYDTPTR 5 P0CE47from65to7
5 
N-Term(SPITC) 1520.56
6 
IDAGKTTTTER 7 P0A6M8from19to
29 
N-Term(SPITC) 1407.58
5 
VQAIEKNR 3 P0A6H5from113t
o120 
N-Term(SPITC) 1172.52
2 
KWTDQSGQDR 2 P0AGE0from88to
97 
N-Term(SPITC) 1435.54
2 
VTVKTDGGPR 3 P0AEG8from7to1
6 
N-Term(SPITC) 1244.54
8 
EAAATAGEKEDAPR 2 P45577from123to
136 
N-Term(SPITC) 1630.64
9 
AKASQLDEAR 2 P62620from354to
363 
N-Term(SPITC) 1303.54
4 
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sequence PSMs protein accessions Modification MH+(Da
) 
SPEQQKVVDR 4 P0ADI4from102to
111 
N-Term(SPITC) 1400.58
8 
LPDINNEASLR 2 P75961from64to7
4 
N-Term(SPITC) 1456.62
8 
ILSKDEGGR 7 P0CE47from311to
319 
N-Term(SPITC) 1189.50
2 
KDLTAADGQTR 4 P77395from245to
255 
N-Term(SPITC) 1390.57
6 
KASVEIDR 2 P0A7L3from85to9
2 
N-Term(SPITC) 1132.47
9 
STGTSGAGSDVEKVR 6 P0A9M8from592t
o606 
N-Term(SPITC) 1665.68
6 
AEQAALQADKR 1 P0AFK0from144to
154 
N-Term(SPITC) 1415.61
8 
KSPFDSGGR 2 P07012from204to
212 
N-Term(SPITC) 1165.43
6 
EAAGSALKGDR 2 P0ACB2from206t
o216 
N-Term(SPITC) 1289.52
5 
LQQVGDKPR 4 P0AFG0from115t
o123 
N-Term(SPITC) 1255.56 
SQGQEEAEKLR 1 P0ABC3from240t
o250 
N-Term(SPITC) 1489.60
7 
EQEAAELKR 2 P0A705from177to
185 
N-Term(SPITC) 1288.53
3 
ALGKDDEVR 10 P09373from674to
682 
N-Term(SPITC) 1217.49
2 
QLSNDVNAMR 1 P69776from43to5
2 
N-Term(SPITC) 1362.51
1 
IPEKSVSQSDR 1 P0ABH9from436t
o446 
N-Term(SPITC) 1460.61
8 
SNQFGDTR 6 P0AEH5from2to9 N-Term(SPITC) 1139.38
5 
KLLDEGR 14 P0CE47from264to
270 
N-Term(SPITC) 1045.44
6 
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sequence PSMs protein accessions Modification MH+(Da
) 
EVKELTER 5 P0ADG7from108t
o115 
N-Term(SPITC) 1218.51
4 
VAKIYGDR 3 P0AFG3from574t
o581 
N-Term(SPITC) 1136.49
7 
VYKNYDPR 3 P0ABH7from308t
o315 
N-Term(SPITC) 1269.50
2 
DAFTLVLAR 3 P76254from233to
241 
N-Term(SPITC) 1220.53
9 
GDKSMALR 3 P02359from112to
119 
N-Term(SPITC) 1092.42
9 
DLLKEQNNR 2 P0A742from127to
135 
N-Term(SPITC) 1344.57
1 
ALQSSINEDKAH 2 P0AD24from64to
75 
N-Term(SPITC) 1527.62 
ISIKDTR 4 P22259from450to
456 
N-Term(SPITC) 1047.46
6 
AENQYYGTGR 6 P0A7X3from2to11 N-Term(SPITC) 1373.49
2 
NIDADKVNPR 2 P0AFG8from876t
o885 
N-Term(SPITC) 1356.56
7 
IQAEKSQQSSY 6 P69913from51to6
1 
N-Term(SPITC) 1483.58
2 
VKAPGFGDR 1 P0A6F5from276to
284 
N-Term(SPITC) 1161.48
4 
HAQAEGIR 2 P0AFI0from40to4
7 
N-Term(SPITC) 1096.43
8 
QLGDKPADVR 8 P15254from849to
858 
N-Term(SPITC) 1313.56
3 
MELSSLTAVSPVDGR 3 P0AB89from1to15 N-Term(SPITC) 1776.76
2 
VDGTKPVAEVR 3 P69441from196to
206 
N-Term(SPITC) 1385.62
7 
TLGADALEPKR 1 P0A9W3from537t
o547 
N-Term(SPITC) 1385.62
4 
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sequence PSMs protein accessions Modification MH+(Da
) 
TIVR 1 P32717from253to
270 
N-Term(SPITC) 703.289
6 
ISNVELSKR 2 P0ACJ0from29to3
7 
N-Term(SPITC) 1260.57
7 
IAPLDADR 2 P16685from116to
123 
N-Term(SPITC) 1085.44
2 
AISTIAESKR 3 P69908from22to3
1 
N-Term(SPITC) 1290.58 
KGSENYALTTNQGVR 6 P21179from73to8
7 
N-Term(SPITC) 1852.79
1 
ITKEDIER 3 P0ABK2from366t
o373 
N-Term(SPITC) 1218.51
6 
VKAEMENLR 1 P09372from65to7
3 
N-Term(SPITC) 1304.55
4 
AKDGLALSSR 4 P31663from180to
189 
N-Term(SPITC) 1232.54
3 
TPDQVKEIAR 5 P33570from528to
537 
N-Term(SPITC) 1371.60
9 
YAPNAKDLAGR 4 P0AC41from276to
286 
N-Term(SPITC) 1390.59 
LAKEDPSFR 15 P0A6M8from438t
o446 
N-Term(SPITC) 1277.53
3 
IAAGADISKAAAGR 2 P0ACF4from10to2
3 
N-Term(SPITC) 1486.68
3 
LLKAANTGPHAAR 1 P0ADH5from21to
33 
N-Term(SPITC) 1534.72
8 
GIPADKISAR 3 P0A910from289to
298 
N-Term(SPITC) 1242.56 
KAELESAALNAR 8 P08312from75to8
6 
N-Term(SPITC) 1487.65
6 
QTVDEALKDAQTR 6 P0AEX9from381to
393 
N-Term(SPITC) 1689.72
7 
IDDGELHGESPGDR 1 P64503from12to2
5 
N-Term(SPITC) 1711.63
2 
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sequence PSMs protein accessions Modification MH+(Da
) 
PAITEDEIR 1 P39283from8to16 N-Term(SPITC) 1258.50
6 
AESFTTTNR 2 P0ADN2from2to1
0 
N-Term(SPITC) 1241.45
4 
SHLDEVIAR 3 P64455from2to10 N-Term(SPITC) 1254.53
2 
IKEAFDTGVR 3 P0A853from155to
164 
N-Term(SPITC) 1350.57
7 
AFDQIDNAPEEKAR 17 P0CE47from46to5
9 
N-Term(SPITC) 1818.73
7 
VAQVDKTAVDTYR 2 P36683from830to
842 
N-Term(SPITC) 1680.73
5 
NLTGKEADAALGR 3 P0A825from327to
339 
N-Term(SPITC) 1530.67
2 
LSPKESEVLR 5 P69407from151to
160 
N-Term(SPITC) 1372.62
8 
NKDGIPAVVER 22 P60422from70to8
0 
N-Term(SPITC) 1412.61
8 
GIGPAYEDKVAR 9 P0A7D4from133t
o144 
N-Term(SPITC) 1490.63
5 
ILDPTKVTR 3 P0A6F5from493to
501 
N-Term(SPITC) 1257.59
7 
AEQTVEAPSVDAR 1 P08506from28to4
0 
N-Term(SPITC) 1587.63
9 
NEPDAVAEKLAR 3 P0A8L1from9to20 N-Term(SPITC) 1527.64
9 
AKIVDEIGLPR 2 P25553from189to
199 
N-Term(SPITC) 1425.69 
QYIEKDAALER 1 P63284from321to
331 
N-Term(SPITC) 1550.66
6 
FNSLTKEQQQDVITR 5 P09373from740to
754 
N-Term(SPITC) 2021.90
6 
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sequence PSMs protein accessions Modification MH+(Da
) 
KFEELVQTR 12 P0A6Y8from528to
536 
N-Term(SPITC) 1364.58
7 
MSTIEER 4 P0A6A8from1to7 N-Term(SPITC) 1080.38
2 
FNMHLWLSPEIAR 1 P39172from140to
152 
N-Term(SPITC) 1828.78
9 
VGFFNPIASEKEEGTR 2 P0A7T3from36to5
1 
N-Term(SPITC) 1995.85 
KENNLGADVVLR 6 P07118from456to
467 
N-Term(SPITC) 1542.69
8 
LGISTLDDVLTDIR 1 P77541from59to7
2 
N-Term(SPITC) 1745.80
3 
MQIDSKPEELDR 3 P63284from403to
414 
N-Term(SPITC) 1675.68
9 
VAIFNAATGKADR 4 P60624from70to8
2 
N-Term(SPITC) 1548.70
1 
VKAALELAEQR 11 P0A7V8from155t
o165 
N-Term(SPITC) 1442.67
4 
TLTQEDVEALEKR 3 P0A8M3from111t
o123 
N-Term(SPITC) 1746.75
8 
FLSALAGENDPEAKR 3 P04079from294to
308 
N-Term(SPITC) 1832.78
9 
ELVTAAKLGGGDPDANPR 2 P0A8A0from31to
48 
N-Term(SPITC) 1995.89
6 
VLQEAADKSNPLIER 1 P0A7B1from21to3
5 
N-Term(SPITC) 1897.88
8 
GVTVDKMTELR 5 P0A7J3from32to4
2 
N-Term(SPITC) 1463.63
2 
ILENGEVKPLDVK 1 P0A6F9from48to9
7 
N-Term(SPITC) 1668.80
4 
KGFIDVEQVR 4 P37744from261to
270 
N-Term(SPITC) 1405.62 
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sequence PSMs protein accessions Modification MH+(Da
) 
VKLDTTGLIDR 2 P0A953from52to6
2 
N-Term(SPITC) 1445.67
3 
IETLNFMEPQSAADLIR 1 P0ABZ1from107to
123 
N-Term(SPITC) 2162.95
7 
LFGKPEIDGSR 4 P33221from352to
362 
N-Term(SPITC) 1433.61
5 
GITINTSHVEYDTPTR 2 P0CE47from60to7
5 
N-Term(SPITC) 2018.86
3 
AYADDKAIVGGIAR 6 P0ABD5from94to
107 
N-Term(SPITC) 1634.73
7 
ESYTKEDLLASGR 5 P0A6Q3from6to1
8 
N-Term(SPITC) 1683.68
9 
ILLDTKGPEIR 6 P0AD61from63to
73 
N-Term(SPITC) 1469.71
5 
IFDLGNVIVDIDFNR 3 P0A8Y3from4to18 N-Term(SPITC) 1964.89
9 
AKVDQLSNDVNAMR 8 P69776from39to5
2 
N-Term(SPITC) 1775.76
1 
NILNELQKDGR 2 P0ACJ0from18to2
8 
N-Term(SPITC) 1514.67
2 
ATYYSNDFR 3 P0A6N4from2to1
0 
N-Term(SPITC) 1351.46
8 
DKLEPYFTEGR 2 P00961from623to
633 
N-Term(SPITC) 1569.64 
LGEYLKPLAER 2 P0A9S5from21to3
1 
N-Term(SPITC) 1503.69
6 
KDDTIPAIISHDE 2 P0AE18from252to
264 
N-Term(SPITC) 1668.68
5 
VVSMPSTDAFDKQDAAYR 2 P27302from580to
597 
N-Term(SPITC) 2215.91
7 
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sequence PSMs protein accessions Modification MH+(Da
) 
TLNDAVEVKHADNTLTFG
PR 
8 P0AG55from36to
55 
N-Term(SPITC) 2413.08
4 
LTTDKGEWLLYR 2 P00961from108to
119 
N-Term(SPITC) 1709.75
2 
GFAVTPPELTKDDER 3 P62707from118to
132 
N-Term(SPITC) 1889.79 
AEHWIDVR 5 P23857from20to2
7 
N-Term(SPITC) 1240.49 
SEFITVAR 6 P0ABA4from2to9 N-Term(SPITC) 1137.46
8 
QAGELQEKLIAVNR 4 P0A7W1from5to2
0 
N-Term(SPITC) 1783.84
1 
SQVSTEFIPTR 4 P0AEZ9from2to12 N-Term(SPITC) 1479.61
7 
FGVPLVR 1 P00864from386to
392 
N-Term(SPITC) 1002.46
1 
NKVTDAEIAEVLAR 6 P63284from529to
542 
N-Term(SPITC) 1743.81 
SGITFSQELKDSGMR 2 P0A953from31to4
5 
N-Term(SPITC) 1870.77
3 
VGGSTYQVPVEVR 2 P02359from80to9
2 
N-Term(SPITC) 1605.69
2 
ALYDSEKDAYLIGR 2 P22106from125to
138 
N-Term(SPITC) 1828.77
9 
LASSPSPLNPGTNVAR 2 P0AE22from24to3
9 
N-Term(SPITC) 1795.80
1 
WQTLSAKSFPLPR 1 P45423from129to
141 
N-Term(SPITC) 1745.82
6 
TSGGELDKLLAAGR 1 P16700from324to
337 
N-Term(SPITC) 1602.73
5 
118 
 
sequence PSMs protein accessions Modification MH+(Da
) 
KIDGIPALLDR 16 P37769from68to7
8 
N-Term(SPITC) 1425.68
3 
PVITLPDGSQR 2 P0A8M3from2to1
2 
N-Term(SPITC) 1397.62
8 
QTFAQKAQAFEQDR 3 P0AEU7from92to
105 
N-Term(SPITC) 1882.78 
INKALDFIAER 3 P04805from457to
467 
N-Term(SPITC) 1504.69 
NIAEAASGIDKLVSR 3 P0ABU5from197t
o211 
N-Term(SPITC) 1758.81
5 
TELLNSSYDVSR 5 P16700from26to3
7 
N-Term(SPITC) 1598.64
2 
NVYIKEAFDTGVR 21 P0A853from152to
164 
N-Term(SPITC) 1726.75
8 
MNIIEANVATPDAR 4 P61714from1to14 N-Term(SPITC) 1729.74
2 
ALLPLVEEKADR 5 P07003from318to
329 
N-Term(SPITC) 1568.74
3 
MSHLDEVIAR 2 P64455from1to10 N-Term(SPITC) 1385.56
5 
SANIALVLYKDGER 3 P60422from88to1
01 
N-Term(SPITC) 1763.81
4 
SLVWDEAQKLTGR 3 P21179from301to
313 
N-Term(SPITC) 1717.78 
AAILSQSQLTALFGQYR 1 P37177from151to
167 
N-Term(SPITC) 2081.97
1 
IWDSTDALELKEVPER 3 P0A9P0from162to
177 
N-Term(SPITC) 2115.92
7 
IIDQEVKALIER 3 P0AAI3from544to
555 
N-Term(SPITC) 1641.79
1 
MYQDLIR 1 P63224from1to7 N-Term(SPITC) 1153.45 
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sequence PSMs protein accessions Modification MH+(Da
) 
VVAILLNDEVR 1 P21179from602to
612 
N-Term(SPITC) 1455.69
1 
LGEGDKVVSLIVPR 2 P0AES4from726to
739 
N-Term(SPITC) 1696.83
6 
EQIIFPEIDYDKVDR 3 P62399from134to
148 
N-Term(SPITC) 2094.90
7 
TSENPLLALR 4 P0A9J8from2to11 N-Term(SPITC) 1328.59
4 
MESLTLQPIAR 2 P0A6D3from1to1
1 
N-Term(SPITC) 1473.65
5 
VQELAEKLYSELR 2 P16659from489to
501 
N-Term(SPITC) 1792.82
3 
YLDVSTLKELAR 1 P0A784from131to
142 
N-Term(SPITC) 1622.76 
AVTNVAELNALVER 4 P0A9Q7from2to1
5 
N-Term(SPITC) 1713.78 
LDELNNVDDFR 1 P32171from441to
451 
N-Term(SPITC) 1564.61
9 
MENYLIDNLDR 2 P0ACI6from1to11 N-Term(SPITC) 1610.63
5 
MQDPIADMLTR 1 P0A7W7from3to1
3 
N-Term(SPITC) 1505.59
1 
MSVVPVADVLQGR 2 P0A8M0from1to1
3 
N-Term(SPITC) 1585.71
9 
QLPDKAIDLIDEAASSIR 2 P63284from385to
402 
N-Term(SPITC) 2170.01
8 
TMYATLEEAIDAAR 1 P25738from2to15 N-Term(SPITC) 1769.72
8 
MDALELLINR 1 P0ACY1from1to10 N-Term(SPITC) 1402.61
8 
STQLDPTQLAIEFLR 1 P64476from2to16 N-Term(SPITC) 1946.89
8 
120 
 
sequence PSMs protein accessions Modification MH+(Da
) 
ILLNDEVR 1 P21179from605to
612 
N-Term(SPITC) 1186.52
6 
ELLMALR 1 P0AF10from111to
117 
N-Term(SPITC) 1060.45
4 
VKAQDVQR 1 P68919from72to7
9 
N-Term(SPITC) 1158.50
6 
GTVVTGR 1 P0CE47from225to
231 
N-Term(SPITC) 904.366
9 
NDDAKAVQR 2 P0AG16from484t
o492 
N-Term(SPITC) 1231.48
6 
KTLAEGQR 2 P0A972from42to4
9 
N-Term(SPITC) 1117.48 
KAIATPDR 2 P0ABJ1from221to
228 
N-Term(SPITC) 1086.47
5 
TTLSTDPKR 1 P22259from230to
263 
N-Term(SPITC) 1233.53
1 
EEIKEVAPHR 2 P0A6H1from50to
59 
N-Term(SPITC) 1422.61
1 
ATVSMR 2 P0A7V0from2to7 N-Term(SPITC) 879.316
2 
IISAKDHGDSFR 1 P37902from181to
192 
N-Term(SPITC) 1560.66 
NAVVTAADKASANR 1 P00805from153to
166 
N-Term(SPITC) 1602.71
3 
LTGKEADAALGR 2 P0A825from328to
339 
N-Term(SPITC) 1416.62
3 
KDLANAIR 2 P33570from4to11 N-Term(SPITC) 1115.50
5 
GAPTITKDGVSVAR 1 P0A6F5from45to5
8 
N-Term(SPITC) 1586.73
5 
MNEQYSALR 1 P00864from1to9 N-Term(SPITC) 1326.49
3 
TTIVSVR 2 P0A7B8from2to8 N-Term(SPITC) 990.436 
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sequence PSMs protein accessions Modification MH+(Da
) 
TDLTAQEPAWQTR 1 P33599from2to14 N-Term(SPITC) 1731.70
8 
VDYPLPPTGSR 1 P76193from24to3
4 
N-Term(SPITC) 1416.59
3 
VTYPLPTDGSR 1 P0AAX8from25to
35 
N-Term(SPITC) 1420.59
2 
MQVSVETTQGLGR 1 P0A850from1to13 N-Term(SPITC) 1620.68
4 
DLQSIADYPVKVR 1 P23830from420to
432 
N-Term(SPITC) 1718.78
9 
LIVIDFIDMTPVR 5 P21513from342to
354 
N-Term(SPITC) 1746.81
1 
TTIVDSNLPVAR 1 P39160from2to13 N-Term(SPITC) 1500.67
4 
DWYVVDATGKTLGR 3 P0AA10from14to
27 
N-Term(SPITC) 1795.76
6 
MFEINPVNNR 2 P07012from1to10 N-Term(SPITC) 1448.56
9 
SAQPVDIQIFGR 1 P0ADS2from2to1
3 
N-Term(SPITC) 1545.69
8 
MIDTTLPLTDIHR 1 P22333from1to13 N-Term(SPITC) 1740.77
7 
TQTLSQLENSGAFIER 1 P33195from2to17 N-Term(SPITC) 2008.87
6 
SVVPVADVLQGR 4 P0A8M0from2to1
3 
N-Term(SPITC) 1454.66
8 
SQNVYQFIDLQR 5 P09832from2to13 N-Term(SPITC) 1725.73
2 
TSLVVPGLDTLR 1 P0AAY6from2to1
3 
N-Term(SPITC) 1485.71
2 
SNDVIQDDVFR 1 P52643from265to
282 
N-Term(SPITC) 1522.60
9 
GVEVIAVDR 1 P33221from35to4
3 
N-Term(SPITC) 1172.50
9 
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) 
VDAYDR 1 P77690from213to
218 
N-Term(SPITC) 953.308
3 
ESLLLPSPFDYSR 1 P76257from418to
430 
N-Term(SPITC) 1738.74
3 
IDPR 1 P08244from27to3
9 
N-Term(SPITC) 715.253
7 
EQWDAQR 1 P37672from77to8
3 
N-Term(SPITC) 1147.39
5 
ISGADLTR 1 P37610from18to2
5 
N-Term(SPITC) 1047.42
2 
GDEAYSGSR 1 P0A853from70to7
8 
N-Term(SPITC) 1156.36
3 
HGESQWNKENR 1 P62707from11to2
1 
N-Term(SPITC) 1599.59
6 
QAKDVAESDR 2 P36683from371to
380 
N-Term(SPITC) 1333.50
7 
EQEKGLDR 2 P0A853from118to
125 
N-Term(SPITC) 1189.45
9 
PEAIPELLER 1 P0AFD1from155t
o164 
N-Term(SPITC) 1381.61
7 
VIYVAADR 1 P76157from14to3
5 
N-Term(SPITC) 1121.48
2 
EDEGLADR 1 P0AE08from113to
120 
N-Term(SPITC) 1119.38 
PDNAGILR 1 P46879from58to6
5 
N-Term(SPITC) 1070.44
2 
PQGQLQDIER 1 P15043from356to
365 
N-Term(SPITC) 1398.57
3 
YEGIDER 1 P0A873from115to
121 
N-Term(SPITC) 1096.37 
EQQVALR 1 P71229from139to
145 
N-Term(SPITC) 1058.44
2 
EHLSQEVLGKR 1 P0AE88from179to
189 
N-Term(SPITC) 1510.67
2 
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sequence PSMs protein accessions Modification MH+(Da
) 
YPEGTKLTGR 2 P0AG67from274t
o283 
N-Term(SPITC) 1336.56
4 
VGVETFKAEVER 2 P17846from314to
325 
N-Term(SPITC) 1578.67
9 
EFYEKPTTER 1 P68679from36to4
5 
N-Term(SPITC) 1514.59 
VLEEKGFR 1 P0A9L8from242to
249 
N-Term(SPITC) 1192.50
9 
SQLNYSEENLKQAR 1 P21888from300to
313 
N-Term(SPITC) 1894.80
8 
AEGLFKEER 1 P0AB77from18to2
6 
N-Term(SPITC) 1293.52
2 
EDGTIDFDDGSKTENTR 1 P22259from317to
333 
N-Term(SPITC) 2114.79
1 
TYDDDPTKYQDLR 2 P0AEM9from175t
o187 
N-Term(SPITC) 1844.70
4 
LDYSKGLPER 1 P31677from264to
273 
N-Term(SPITC) 1392.58
7 
IKEEDFIDR 1 P0AES4from572to
580 
N-Term(SPITC) 1379.55
3 
YAIDAEKIGR 1 P37759from304to
313 
N-Term(SPITC) 1350.57
8 
IINGEVPEGLKGR 1 P63284from223to
235 
N-Term(SPITC) 1596.74 
AKITVPVDATEEQVR 2 P07813from812to
826 
N-Term(SPITC) 1870.87
8 
HGYAFNELDLGKR 1 P0ADN2from38to
50 
N-Term(SPITC) 1734.73
5 
AGEGAKVIELQGIAGTSAA
R 
2 P02925from126to
164 
N-Term(SPITC) 2114.00
6 
LTLDLGGEKR 2 P00959from601to N-Term(SPITC) 1316.59
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sequence PSMs protein accessions Modification MH+(Da
) 
610 5 
EHWIDVR 1 P23857from21to2
7 
N-Term(SPITC) 1169.44
4 
VPGLDFKR 1 P15639from374to
381 
N-Term(SPITC) 1146.50
6 
SIVPNALGKDDEVR 1 P09373from669to
682 
N-Term(SPITC) 1727.76
4 
IAFVNKMDR 1 P0A6M8from138t
o146 
N-Term(SPITC) 1308.55
4 
FDPEFEKISR 1 P13029from382to
391 
N-Term(SPITC) 1482.6 
LFADEPTGNLDR 1 P0A9T8from168to
179 
N-Term(SPITC) 1562.61
6 
ATVNQLVR 1 P0A7S3from2to9 N-Term(SPITC) 1115.49
7 
SLIGPDGEQYKLPR 1 P0A9Q1from150t
o163 
N-Term(SPITC) 1787.8 
AIGEAKDDDTADILTAASR 2 P0ABT2from134to
153 
N-Term(SPITC) 2147.90
8 
EAEGQDFQLYPGELGKR 1 P0A8P3from13to2
9 
N-Term(SPITC) 2151.91
5 
EITASLVKELR 1 P0A6P1from3to13 N-Term(SPITC) 1473.70
5 
GSLPIALDEVITDGHKR 2 P0A9Q7from465t
o481 
N-Term(SPITC) 2035.95
1 
QLNITGNNVEITEALR 1 P0AFX0from2to17 N-Term(SPITC) 1999.92
3 
VYSKLTSENPIDLVR 2 P0A991from259to
273 
N-Term(SPITC) 1948.91 
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sequence PSMs protein accessions Modification MH+(Da
) 
ELLSQYDFPGDDTPIVR 1 P0CE47from156to
172 
N-Term(SPITC) 2179.93
9 
EVTYGDVTLDFGKPFEK 2 P0A8N3from310t
o330 
N-Term(SPITC) 2159.93
5 
LYTTNADGELITIDTADNKI
LSR 
2 P76116from199to
221 
N-Term(SPITC) 2752.27
2 
ETEGQALKALIEQR 1 P23839from146to
159 
N-Term(SPITC) 1800.82
5 
ANQANIPVITLDR 1 P02925from103to
115 
N-Term(SPITC) 1639.75 
SGIIELPADAPIGTDIR 1 P07395from132to
148 
N-Term(SPITC) 1952.91
5 
SNQEPATILLIDDHPMLR 1 P0AF28from2to19 N-Term(SPITC) 2278.02
6 
QLIDGIKDLAVQYR 2 P0AB89from149to
162 
N-Term(SPITC) 1846.87
4 
LPDWDAKIANLSGGER 2 P0A9W3from153t
o168 
N-Term(SPITC) 1956.84
3 
IVGLEIGADDYIPKPFNPR 1 P0AA16from92to
110 
N-Term(SPITC) 2329.09
5 
VTPTVLQKGR 1 P34749from306to
315 
N-Term(SPITC) 1313.63
6 
SVLQVLHIPDER 1 P0A6K3from2to13 N-Term(SPITC) 1620.74
8 
EFEKAAASR 1 P00448from116to
124 
N-Term(SPITC) 1223.47
7 
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sequence PSMs protein accessions Modification MH+(Da
) 
CGIVGAIAQR 3 P17169from2to11 N-Term(SPITC); 
C1(Carbamido
methyl) 
1259.52
8 
CAQVEALEIIVTAMLR 1 P0AAN9from23to
38 
N-Term(SPITC); 
C1(Carbamido
methyl) 
2031.94
6 
SQVQSGILPEHCR 3 P76536from2to14 N-Term(SPITC); 
C12(Carbamido
methyl) 
1725.71
3 
AASEAVKDAALSCDQFFV
NHR 
3 P0A7V0from75to
95 
N-Term(SPITC); 
C13(Carbamido
methyl) 
2551.06
5 
LCNQKGVER 1 P0AAJ8from176to
184 
N-Term(SPITC); 
C2(Carbamido
methyl) 
1318.54
4 
ECISENQILKR 2 P0A9C0from70to8
0 
N-Term(SPITC); 
C2(Carbamido
methyl) 
1604.67
9 
TICPDQKGLIAR 1 P37051from11to2
2 
N-Term(SPITC); 
C3(Carbamido
methyl) 
1586.70
4 
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sequence PSMs protein accessions Modification MH+(Da
) 
QVCAKLSASASDYLR 1 P77439from218to
232 
N-Term(SPITC); 
C3(Carbamido
methyl); 
K5(Guanidinyl) 
1925.83
6 
ALPCPVR 1 P05827from172to
178 
N-Term(SPITC); 
C4(Carbamido
methyl) 
1027.42
5 
FLTCGSVDDGKSTLIGR 1 P23845from30to4
6 
N-Term(SPITC); 
C4(Carbamido
methyl) 
2040.87
8 
GALDCSGVKDR 7 P0A7S3from100to
110 
N-Term(SPITC); 
C5(Carbamido
methyl) 
1392.53 
IVQACTQDKQANFK 2 P0AES9from83to1
10 
N-Term(SPITC); 
C5(Carbamido
methyl) 
1865.79
9 
LLSLCGPFDDNIKQLER 1 P0A9K3from18to3
4 
N-Term(SPITC); 
C5(Carbamido
methyl) 
2233.00
6 
KVEADCR 8 P60422from183to
189 
N-Term(SPITC); 
C6(Carbamido
methyl) 
1092.39
6 
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sequence PSMs protein accessions Modification MH+(Da
) 
TGFAECAFEDAAR 1 P0A9U8from250t
o262 
N-Term(SPITC); 
C6(Carbamido
methyl) 
1659.58 
LIIFLICLLVFWLWLHK 2 P0AFS1from167to
188 
N-Term(SPITC); 
C7(Carbamido
methyl) 
2442.29
5 
TFFAEFASCLTELQTR 1 P16694from675to
690 
N-Term(SPITC); 
C9(Carbamido
methyl) 
2135.87
4 
DHTASLGACEIPR 1 P0A8P1from192to
204 
N-Term(SPITC); 
C9(Carbamido
methyl) 
1641.64
7 
GKSVEEILGK 5 P0A7W1from158t
o167 
N-Term(SPITC); 
K10(Guanidinyl) 
1316.59
4 
SATPEQELGKLPLGSR 1 P00864from684to
699 
N-Term(SPITC); 
K10(Guanidinyl) 
1939.89
9 
PLSLTLIPESKPGNGK 6 P0AEH1from282t
o319 
N-Term(SPITC); 
K11(Guanidinyl) 
1907.94
7 
IWDSTDALELKEVPER 2 P0A9P0from162to
177 
N-Term(SPITC); 
K11(Guanidinyl) 
2157.95
3 
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sequence PSMs protein accessions Modification MH+(Da
) 
ILENGEVKPLDVK 1 P0A6F9from48to9
7 
N-Term(SPITC); 
K13(Guanidinyl) 
1710.82
4 
ALLYEETAESVEKR 1 P0ACG8from82to
95 
N-Term(SPITC); 
K13(Guanidinyl) 
1894.81
7 
SSGDPADQKYVELK 1 P0AEH5from27to
42 
N-Term(SPITC); 
K14(Guanidinyl) 
1793.75 
TPFAPIVNTATSLKPVR 1 P0A996from106to
122 
N-Term(SPITC); 
K14(SPITC) 
2241.99
9 
LANELSDAAENKGTAVK 4 P02359from120to
138 
N-Term(SPITC); 
K17(Guanidinyl) 
1987.88
7 
IASDNVLGGKIAGDYIAK 1 P02925from126to
164 
N-Term(SPITC); 
K18(Guanidinyl) 
2061.99
1 
TKSELIER 1 P0A6Y1from2to9 N-Term(SPITC); 
K2(Guanidinyl) 
1232.53
7 
AKSFIVR 1 P46850from318to
324 
N-Term(SPITC); 
K2(Guanidinyl) 
1077.50
5 
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sequence PSMs protein accessions Modification MH+(Da
) 
GKTVINFDNAIIAAGSR 1 P0A9P0from132to
148 
N-Term(SPITC); 
K2(Guanidinyl) 
2003.95
2 
NKVTDAEIAEVLAR 1 P63284from529to
542 
N-Term(SPITC); 
K2(Guanidinyl) 
1785.81
5 
TKTGELSIHCTELR 1 P0A8N3from102t
o144 
N-Term(SPITC); 
K2(Guanidinyl); 
C10(Carbamido
methyl) 
1901.81
8 
IHKNMSIER 1 P0ADG7from70to
78 
N-Term(SPITC); 
K3(Guanidinyl) 
1384.59
1 
AGKAGVEVDDR 1 P0A9P0from282to
292 
N-Term(SPITC); 
K3(Guanidinyl) 
1373.56
3 
AAKSDNGASNLLR 1 P0ABC7from366t
o378 
N-Term(SPITC); 
K3(Guanidinyl) 
1573.68 
TDKLTSLR 1 P0A870from2to9 N-Term(SPITC); 
K3(Guanidinyl) 
1190.52
4 
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sequence PSMs protein accessions Modification MH+(Da
) 
TTKLHVHDENNECGIGDV
VEIR 
1 P0AG63from41to
62 
N-Term(SPITC); 
K3(Guanidinyl); 
C13(Carbamido
methyl) 
2792.2 
SAKTENELEEIK 1 P30958from1032t
o1049 
N-Term(SPITC); 
K3(Guanidinyl); 
K12(Guanidinyl) 
1689.72
8 
LQKIFPIR 1 P0A8G0from145t
o152 
N-Term(SPITC); 
K3(SPITC) 
1444.57
4 
VIKHPHAVLLLDEIEK 2 P0ABH9from553t
o592 
N-Term(SPITC); 
K3(SPITC) 
2284.04
3 
LSKVLPNPDNVELIR 1 P77397from257to
271 
N-Term(SPITC); 
K3(SPITC) 
2136.93
9 
DEKTSEWDER 1 P15640from320to
329 
N-Term(SPITC); 
K3(SPITC) 
1724.50
2 
ANIK 1 P52143from596to
730 
N-Term(SPITC); 
K4(Guanidinyl) 
702.269
5 
SEFKNPER 1 P39277from208to
215 
N-Term(SPITC); 
K4(Guanidinyl) 
1263.48
5 
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sequence PSMs protein accessions Modification MH+(Da
) 
PSEK 1 P21507from386to
402 
N-Term(SPITC); 
K4(Guanidinyl) 
717.231
4 
APTKSLQQAAR 4 P0A6X1from391to
401 
N-Term(SPITC); 
K4(SPITC) 
1600.60
5 
ADAQK 1 P0AES9from22to1
10 
N-Term(SPITC); 
K5(Guanidinyl) 
789.263
8 
ADAQKAADNK 1 P0AES9from22to1
10 
N-Term(SPITC); 
K5(Guanidinyl) 
1288.51
1 
VDGTKPVAEVR 1 P69441from196to
206 
N-Term(SPITC); 
K5(Guanidinyl) 
1427.65
1 
LMTDKYEIDAR 1 P09836from13to2
3 
N-Term(SPITC); 
K5(Guanidinyl) 
1611.65
2 
GEVNKVIEQAR 1 P00956from817to
827 
N-Term(SPITC); 
K5(Guanidinyl) 
1499.68 
FNQQKNTLLVLSHESR 1 P39382from211to
226 
N-Term(SPITC); 
K5(Guanidinyl) 
2171.00
9 
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sequence PSMs protein accessions Modification MH+(Da
) 
EALEKAEEAGVDLVEISPN
AEPPVCR 
1 P0A707from41to6
6 
N-Term(SPITC); 
K5(Guanidinyl); 
C25(Carbamido
methyl) 
3079.36
5 
IIDFKTALTASGR 1 P27254from253to
265 
N-Term(SPITC); 
K5(SPITC) 
1822.73
2 
SLINTK 2 P0AE08from2to32 N-Term(SPITC); 
K6(Guanidinyl) 
932.396
2 
DPTLAK 1 P52101from80to9
1 
N-Term(SPITC); 
K6(Guanidinyl) 
901.350
2 
WADASKADR 1 P09147from300to
308 
N-Term(SPITC); 
K6(Guanidinyl) 
1276.47
1 
NAVDAAKALGIDAR 1 P0ABP8from137t
o150 
N-Term(SPITC); 
K7(Guanidinyl) 
1641.73
1 
APLMTDKYEIDAR 1 P09836from11to2
3 
N-Term(SPITC); 
K7(Guanidinyl) 
1779.73
6 
ELVTAAKLGGGDPDANPR 1 P0A8A0from31to
48 
N-Term(SPITC); 
K7(Guanidinyl) 
2037.89
8 
134 
 
sequence PSMs protein accessions Modification MH+(Da
) 
SNVPAELK 1 P0A6T9from2to18 N-Term(SPITC); 
K8(Guanidinyl) 
1114.46
7 
VTTEVTVKLLPKPPVAR 1 P0AEP9from219to
235 
N-Term(SPITC); 
K8(SPITC); 
K12(Guanidinyl) 
2320.09
2 
SLSTEATAK 2 P0ADZ4from2to1
7 
N-Term(SPITC); 
K9(Guanidinyl) 
1164.47 
TIMSPWAAKR 1 P0ACY3from174to
183 
N-Term(SPITC); 
K9(Guanidinyl) 
1417.62
7 
SLLNVPAGK 1 P0A7A9from2to4
4 
N-Term(SPITC); 
K9(Guanidinyl) 
1155.52
6 
AEITASLVK 1 P0A6P1from2to13 N-Term(SPITC); 
K9(Guanidinyl) 
1188.53
7 
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Appendix table 2 N-terminal peptides of AspN digestion by iTRAQ labeling 
Sequence 
Protein Group 
Accessions 
q-
Value 
XCor
r 
SpSco
re 
MH+ [Da] 
Delta 
Mass 
[PPM] 
dLGEPLSLITE
SVFAR 
P00350from272to2
87 
0 5.24 
798.9
5 
1891.024
63 
-4.56 
ePLSLITESVF
AR 
P00350from275to2
87 
0.003
72 
1.73 
115.0
6 
1605.906
91 
3.83 
dFAYQGFAR 
P00509from211to2
19 
0 2.19 
310.4
7 
1218.604
78 
-1.23 
dDVIGTLAR 
P00582from115to1
23 
0.002
84 
2.12 
218.2
7 
1103.621
75 
0.13 
dFVPYFR 
P00864from674to6
83 
0.005
93 
1.73 
226.7
2 
1087.574
51 
1.22 
dDLYGIIR P00956from35to42 
0.001
54 
2.41 
209.0
4 
1108.616
5 
0.65 
dQYPEILR 
P00961from203to2
10 
0.001
54 
2.25 
220.8
9 
1177.636
28 
-0.82 
dLQTLTEEAV
R 
P00961from499to5
09 
0 2.14 225.1 
1418.762
86 
-1.26 
dTIQAVLAR 
P00961from544to5
52 
0 3.02 302.3 
1130.669
85 
0.85 
dQSEQVPGM
IER 
P02358from13to24 0 3.72 
615.7
2 
1532.753
83 
0.25 
eQVPGMIER P02358from16to24 
0.003
72 
1.99 
164.0
2 
1202.640
55 
3.88 
dELETTFR P02358from72to79 0 2.76 
277.5
5 
1154.583
18 
-1.47 
aGEGAKVIEL
QGIAGTSAA
R 
P02925from130to1
64 
0 3.77 
430.3
5 
2043.142
43 
3.42 
gEGAKVIELQ
GIAGTSAAR 
P02925from146to1
64 
0.001
54 
3.92 
306.1
3 
1972.107
03 
4.41 
dEMALGALR 
P02925from216to2
24 
0 3.14 
517.5
9 
1119.597
58 
-1.07 
dAIFIEELR 
P04079from428to4
36 
0 3.03 
534.2
7 
1249.696
58 
1.44 
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dFNPSGIILSG
GPESTTEENS
PR 
P04079from48to70 0 4.9 
459.8
4 
2548.207
92 
-9.58 
dDGYLPEALL
NYLVR 
P04805from252to2
66 
0 3.44 
227.5
2 
1895.016
15 
4.82 
dTFIELVR 
P05020from310to3
17 
0 2.57 
226.8
4 
1136.647
63 
0.48 
dDTLVPFLAG
ETVR 
P05020from330to3
43 
0 2.36 
321.4
3 
1676.899
34 
-1.29 
dISEFAPR 
P05055from547to5
54 
0.003
72 
1.98 
196.8
8 
1078.568
41 
-0.4 
dITELEAFR 
P06959from433to4
41 
0 2.99 
334.3
4 
1237.658
49 
0.09 
dSFTIQPGER 
P06968from106to1
15 
0.003
72 
1.68 95.68 
1293.655
2 
-3.29 
dLTTVIENLR 
P06989from190to1
99 
0 2.74 
228.5
8 
1317.762
01 
6.57 
dTLVLLGTQF
PYR 
P07003from267to2
79 
0.001
54 
2.6 
430.2
6 
1666.928
88 
-2.1 
dIGWGSQIR 
P07012from316to3
24 
0.001
54 
2.51 
223.6
1 
1175.631
64 
-1.02 
dAFSVFR 
P07014from199to2
05 
0.001
54 
1.58 
142.6
9 
985.5254
4 
-0.81 
dEWQAVAPS
WR 
P07395from442to4
52 
0 3.46 
737.0
3 
1488.733
08 
-4.05 
dMVIFR 
P08200from148to1
53 
0.003
72 
1.99 
232.7
5 
924.5109
1 
-2.52 
dWGYQLAR 
P08200from226to2
50 
0 2.69 
341.0
4 
1152.594
9 
-0.71 
dAFLQQILLR 
P08200from283to2
92 
0 2.47 
355.2
4 
1360.807
42 
-2.49 
vAIKGPLTTP
VGGGIR 
P08200from97to11
2 
0.001
54 
4.36 
202.3
1 
1680.032
57 
-0.14 
dEFSMSAISIP
R 
P08839from521to5
32 
0 3.3 
501.7
8 
1496.760
3 
1.89 
dFLTLPGYR 
P08997from522to5
30 
0.002
84 
2.35 
267.5
8 
1225.674
85 
1 
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dWQNEVNV
R 
P09373from19to27 0 2.26 
279.5
3 
1303.653
37 
-1.27 
dLENGVNLE
QTIR 
P09373from207to2
19 
0 3.21 
541.5
4 
1644.878
1 
4.16 
dDLAVDLVER 
P09373from575to5
84 
0 2.91 
300.0
9 
1288.688
28 
-1.67 
dTSMGLTPLE
GLVMGTR 
P0A6A3from227to2
43 
0 4.58 
401.0
2 
1921.979
34 
-4.67 
dYTIELVR 
P0A6B7from367to3
74 
0.001
54 
1.98 
123.7
7 
1152.642
38 
0.34 
dLPLIASNFR P0A6F1from84to93 
0.007
02 
1.98 
217.5
5 
1289.744
07 
5.24 
dANIISVSQR P0A6F3from25to34 0 3.04 
481.7
8 
1246.690
84 
-0.19 
dILGTR 
P0A6F3from425to4
30 
0 1.75 99.17 818.4857 -4.17 
dVEGEALATL
VVNTMR 
P0A6F5from253to2
68 
0 4.87 
648.3
2 
1861.991
61 
3.59 
dGVGEEAAI
QGR 
P0A6F5from334to3
45 
0.003
72 
1.83 71.96 
1345.696
95 
7.58 
eGVVAGGGV
ALIR 
P0A6F5from409to4
21 
0.008
03 
2.2 
189.6
2 
1341.807
3 
4.69 
dLGAAGGM
GGMGGMG
GMM 
P0A6F5from531to5
48 
0.001
54 
3.97 
1048.
54 
1701.705 0.15 
dGTTTATVLA
QAIITEGLK 
P0A6F5from87to11
8 
0 4.46 
433.0
1 
2047.148
41 
2.03 
dLIPELQGR 
P0A6H5from317to3
25 
0.001
54 
1.79 
117.6
9 
1184.676
2 
-2.76 
dAGLNIAPFIT
LTR 
P0A6J8from150to1
63 
0 3.57 
476.8
9 
1645.951
95 
5.26 
dPFVGNLTFF
R 
P0A6M8from327to
337 
0 3.21 452.9 
1456.762
38 
-8.27 
dAPIILER 
P0A6M8from401to
408 
0 2.26 
401.9
9 
1070.636
03 
-0.46 
dWMEQEQE
R 
P0A6M8from51to5
9 
0 2.16 
161.0
5 
1394.614
55 
-1.48 
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eVPLSEMFGY
ATQLR 
P0A6M8from657to
671 
0 5.39 
678.6
6 
1884.970
98 
1.3 
dEAPSNVAQ
AVIEAR 
P0A6M8from688to
702 
0 4.8 
599.8
6 
1713.893
71 
0.57 
dFTIEVER 
P0A6M8from94to1
01 
0 2.1 
283.6
1 
1152.603
93 
-1.47 
eVTGFIR 
P0A6P1from252to2
58 
0.001
54 
2.5 
257.1
6 
965.5570
5 
-0.5 
dIELAIENMR P0A6P1from33to42 0 3.66 706.5 
1347.709
03 
-0.56 
dAGYTAVISH
R 
P0A6P9from192to3
71 
0 4.01 
457.9
8 
1333.692
23 
-7.3 
eVHLEGGFV
GMAAAPSG
ASTGSR 
P0A6P9from24to46 0 4.05 501.8 
2332.150
97 
-0.09 
dLLASGR P0A6Q3from12to18 
0.001
54 
1.73 
152.9
9 
875.5090
2 
-1.79 
dEWIVTR P0A6R0from30to36 0 2.08 
218.5
3 
1062.567
55 
-5.99 
eLFFEEIR P0A6X7from28to35 0 2.78 
352.1
4 
1226.656
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